Author: "DRCI" / Topic: medicine - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"DRCI"' showing total 427 results

Start Over Author "DRCI" Topic medicine

427 results on '"DRCI"'

1. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease

Author: Buisson, Anthony, Nancey, Stéphane, Manlay, Luc, Rubin, David, Hebuterne, Xavier, Pariente, Benjamin, Fumery, Mathurin, Laharie, David, Roblin, Xavier, Bommelaer, Gilles, Pereira, Bruno, Peyrin‐biroulet, Laurent, Vuitton, Lucine, Post-Op Study Grp, Ustek, Service d'Hépatologie Gastro-entérologie [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Service d'Hépatogastroentérologie [CHU Lyon-Sud], Hospices Civils de Lyon (HCL), The University of Chicago Medicine [Chicago], Servcie Hépato-gastroentérolgie et Nutrition clinique [CHU Nice], Centre Hospitalier Universitaire de Nice (CHU Nice), Service Gastro-entérologie adulte – Maladies de l’appareil digestif [CHU Lille], CHU Lille, Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service Gastroentérologie [CHU Bordeaux], Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux), Service de Gastro-entérologie et Hépatologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Gastro-Entérologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), 'Francois Aupetit' Association (AFA CrohnRCH), CHU Clermont-Ferrand (DRCI), Centre Hospitalier Universitaire de Lille (CHU Lille), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de l'Environnement Industriel et des Risques, Service de gastroentérologie [CHU Saint-Etienne], and Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne)
Subjects: Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Azathioprine, Antibodies, Monoclonal, Humanized, Gastroenterology, ustekinumab, law.invention, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Gastrointestinal Agents, Randomized controlled trial, Recurrence, law, Internal medicine, Ustekinumab, Secondary Prevention, medicine, Clinical endpoint, Humans, postoperative recurrence, Propensity Score, Retrospective Studies, Crohn's disease, azathioprine, business.industry, Inflammatory Bowel Disease, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Bowel resection, medicine.disease, Control Groups, 3. Good health, Oncology, 030220 oncology & carcinogenesis, Cohort, Propensity score matching, Original Article, Female, 030211 gastroenterology & hepatology, business, Immunosuppressive Agents, medicine.drug
Abstract: International audience; Background: Preventing postoperative recurrence (POR) is a major concern in Crohn's disease (CD). While azathioprine is an option, no data is available on ustekinumab efficacy in this situation.Aims: We compared the effectiveness of ustekinumab versus azathioprine in preventing endoscopic POR in CD.Methods: We retrospectively collected data from all consecutive CD patients treated with ustekinumab after intestinal resection in 9 centers. The control group (azathioprine alone) was composed of patients who participated in a randomized controlled trial conducted in the same centers comparing azathioprine alone or in combination with curcumin. Propensity score analyses (inversed probability of treatment weighting = IPTW) were applied to compare the two groups. The primary endpoint was endoscopic POR (Rutgeerts' index ≥ i2) at 6 months.Results: Overall, 32 patients were included in the ustekinumab group and 31 in the azathioprine group. The propensity score analysis was adjusted on the main risk factors (smoking, fistulizing phenotype, prior bowel resection, resection length >30 cm and ≥2 biologics before surgery) and thiopurines or ustekinumab exposure prior to surgery making the two arms comparable (∣d∣ < 0.2). After IPTW, the rate of endoscopic POR at 6 months was lower in patients treated with ustekinumab compared to azathioprine (28.0% vs. 54.5%, p = 0.029). After IPTW, the rates of i2b-endoscopic POR (Rutgeerts' index ≥ i2b) and severe endoscopic POR (Rutgeerts' index ≥ i3) were 20.8% versus 42.5% (p = 0.066) and 16.9% versus 27.9% (p = 0.24), in the ustekinumab and azathioprine groups, respectively.Conclusion: Ustekinumab seemed to be more effective than azathioprine in preventing POR in this cohort of CD patients.
Published: 2021
Full Text: View/download PDF

2. Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study

Author: Lucas Guillo, David Laharie, Mélanie Serrero, Anne-Laure Pelletier, Hélène Rousseau, Laurent Peyrin-Biroulet, Mathieu Uzzan, Christian Rabaud, Stephanie Viennot, Laurence Picon, Vered Abitbol, Mathias Vidon, Ludovic Caillo, Aurelien Amiot, Laurent Beaugerie, Morgane Amil, Maria Nachury, Jérôme Filippi, Jean-Marc Gornet, Stéphane Nancey, Romain Altwegg, Michael T. Collins, Catherine Reenaers, Felix Goutorbe, Alban Benezech, Grégory Dubourg, Anthony Buisson, Cédric Baumann, Hôpital Nord [CHU - APHM], Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hopital Saint-Louis [AP-HP] (AP-HP), Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de gastro-entérologie [Henri Mondor AP-HP, Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Bordeaux [Bordeaux], Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier de la Côte Basque (CHCB), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire de Liège (CHU-Liège), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service d'Hépatologie Gastro-entérologie [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Infection Inflammation et Interaction Hôtes Pathogènes [CHU Clermont-Ferrand] (3IHP ), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Service d'Hépato-gastro-entérologie [APHP Kremlin-Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Intercommunal de Créteil (CHIC), Centre Hospitalier Henri Duffaut (Avignon), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Délégation à la Recherche Clinique et à l'Innovation [CHRU Nancy] (DRCI), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Microbes évolution phylogénie et infections (MEPHI), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Adult, medicine.medical_specialty, [SDV]Life Sciences [q-bio], HIV Infections, Disease, Inflammatory bowel disease, 03 medical and health sciences, 0302 clinical medicine, Intestinal mucosa, Crohn Disease, Internal medicine, medicine, Humans, Retrospective Studies, Crohn's disease, Hepatology, business.industry, Hazard ratio, Gastroenterology, Retrospective cohort study, medicine.disease, Inflammatory Bowel Diseases, Ulcerative colitis, digestive system diseases, 030220 oncology & carcinogenesis, Concomitant, 030211 gastroenterology & hepatology, Colitis, Ulcerative, business
Abstract: Background and aims Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), and human immunodeficiency virus (HIV) both impact innate and adaptive immunity in the intestinal mucosa. As it is a rare situation, the intersection between HIV and IBD remains unclear, especially the impact of HIV infection on the course of IBD, and the drug safety profile is unknown. Methods We conducted a multicenter retrospective cohort study between January 2019 and August 2020. All adult patients with IBD and concomitant HIV infection were included. Each IBD patient with HIV was matched to two HIV-uninfected IBD patients. Results Overall, 195 patients with IBD were included, including 65 HIV-infected patients and 130 without HIV infection. Of the 65 infected patients, 22 (33.8%) required immunosuppressants and 31 (47.7%) biologics. In the HIV-infected group, the need for immunosuppressants (p = 0.034 for CD and p = 0.012 for UC) and biologics (p = 0.004 for CD and p = 0.008 for UC) was significantly lower. The disease course, using a severity composite criterion, was not significantly different between the two groups for CD (hazard ration (HR) = 1.3 [0.7; 2.4], p = 0.45) and UC (HR, 1.1 [0.5; 2.7], p = 0.767). The overall drug safety profile was statistically similar between the two groups. Conclusion Although HIV-infected patients receive less treatments, the course of their IBD did not differ than uninfected, suggesting that HIV infection might attenuate IBD. The drug safety profile is reassuring, allowing physician to treat these patients according to current recommendations.
Published: 2022
Full Text: View/download PDF

3. Rhinovirus Infection and Familial Atopy Predict Persistent Asthma and Sensitisation 7 Years after a First Episode of Acute Bronchiolitis in Infancy

Author: Valérie Julian, Alexandra Usclade, Flore Amat, Carole Egron, Emmanuelle Rochette, Julie Magnier, Aurélien Mulliez, Bertrand Evrard, Service de Pédiatrie Générale [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service Médecine du Sport et Explorations Fonctionnelles [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Service d'Immunologie [CHU Clermont-Ferrand], Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Hôpital Robert Debré Paris, Hôpital Robert Debré, Dept Sport Med and Funct Explorat, and ROSSI, Sabine
Subjects: medicine.medical_specialty, Allergy, acute bronchiolitis, respiratory syncytial virus, [SDV]Life Sciences [q-bio], atopy, medicine.disease_cause, Pediatrics, Article, RJ1-570, Atopy, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, Internal medicine, medicine, Respiratory function, 030212 general & internal medicine, Asthma, First episode, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, business.industry, Atopic dermatitis, asthma, medicine.disease, 3. Good health, rhinovirus, 030228 respiratory system, Bronchiolitis, Pediatrics, Perinatology and Child Health, Rhinovirus, business
Abstract: Background: We set out to assess the risk factors for asthma outcome in a cohort of infants who experienced their first episode of acute bronchiolitis. Methods: A cohort of 222 infants who were included during a first episode of acute bronchiolitis was prospectively followed. Herein, we present the results of their assessments (symptom history, skin prick tests, specific IgE assay, respiratory function tests) at age seven. Results: Of the 68/222 (30.6%) children assessed at age seven, 15 (22.05%) presented with asthma and were mainly males (p = 0.033), 14 (20%) had respiratory allergies, 17 (25%) presented atopic dermatitis and none had a food allergy. Family history of atopy was associated with asthma and sensitisation to aeroallergens at age seven (p = 0.003, p = 0.007). Rhinovirus (hRV) infection and rhinovirus/respiratory syncytial virus (RSV) co-infection were significantly associated with asthma at age seven (p = 0.035, p = 0.04), but not with the initial severity of bronchiolitis. Eosinophil counts at ages three and seven were significantly higher in the asthmatics (p = 0.01, p = 0.046). Conclusion: Any infant, especially male, presenting a first episode of acute bronchiolitis due to hRV with a family history of atopy should be closely monitored via follow-up due to a higher risk for asthma at school age.
Published: 2021
Full Text: View/download PDF

4. Eucaloric Balanced Diet Improved Objective Sleep in Adolescents with Obesity

Author: Stéphane Walrand, Pascale Duché, Oussama Saidi, Etienne Merlin, Emmanuelle Rochette, Giovanna del Sordo, Eric Doré, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne (UCA)-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Impact de l'Activité Physique sur la Santé (IAPS), Université de Toulon (UTLN), CHU Clermont-Ferrand, Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Unité de Nutrition Humaine (UNH), and Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA)
Subjects: Male, Pediatrics, medicine.medical_specialty, Pediatric Obesity, obesity, Adolescent, [SDV]Life Sciences [q-bio], Polysomnography, Energy balance, Article, Eating, evening meal, Sleep Initiation and Maintenance Disorders, medicine, Humans, TX341-641, Child, Meals, Balance (ability), Caloric Restriction, youth, Nutrition and Dietetics, medicine.diagnostic_test, Nutrition. Foods and food supply, business.industry, Feeding Behavior, medicine.disease, Sleep in non-human animals, Obesity, energy balance, Positive energy, Human nutrition, energy intake, Sleep onset latency, business, Energy Metabolism, Sleep, Food Science
Abstract: Background: A better understanding of the influence of energy balance on sleep in adolescents, particularly those with obesity, could help develop strategies to optimize sleep in these populations. The purpose of this study was to investigate sleep under ad libitum-vs-controlled diets adjusted to energy requirement (eucaloric) among adolescents with obesity and their normal weight controls. Methods: Twenty-eight male adolescents aged between 12 and 15 years, n = 14 adolescents with obesity (OB: BMI ≥ 90th centile) and n = 14 normal weight age matched controls (NW), completed an experimental protocol comprising ad libitum or eucaloric meals for three days, in random order. During the third night of each condition, they underwent in home polysomnography (PSG). Results: An interaction effect of energy intake (EI) was detected (p &lt, 0.001). EI was higher during ad libitum compared to the eucaloric condition (p &lt, 0.001) and in OB compared to NW (p &lt, 0.001) in the absence of any substantial modification to macronutrient proportions. Analyses of energy intake distribution throughout the day showed a significant interaction with both a condition and group effect during lunch and dinner. Sleep improvements were noted in OB group during the eucaloric condition compared to ad libitum with reduced sleep onset latency and N1 stage. Sleep improvements were correlated to reduced EI, especially during the evening meal. Conclusion: Simply adjusting dietary intake to energy requirement and reducing the energy proportion of the evening meal could have therapeutic effects on sleep in adolescents with obesity. However, positive energy balance alone cannot justify worsened sleep among adolescents with obesity compared to normal weight counterparts.
Published: 2021
Full Text: View/download PDF

5. Factors Associated with Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial

Author: Aurélien, Dinh, Clara, Duran, Jacques, Ropers, Frédérique, Bouchand, Benjamin, Davido, Laurène, Deconinck, Morgan, Matt, Olivia, Senard, Aurore, Lagrange, Guillaume, Mellon, Ruxandra, Calin, Sabrina, Makhloufi, Victoire, de Lastours, Emmanuel, Mathieu, Jean-Emmanuel, Kahn, Elisabeth, Rouveix, Julie, Grenet, Jennifer, Dumoulin, Thierry, Chinet, Marion, Pépin, Véronique, Delcey, Sylvain, Diamantis, Daniel, Benhamou, Virginie, Vitrat, Marie-Christine, Dombret, Didier, Guillemot, Bertrand, Renaud, Yann-Erick, Claessens, José, Labarère, Philippe, Aegerter, Jean-Pierre, Bedos, Anne-Claude, Crémieux, Marie, Poupard, Université Paris-Saclay, Service des Maladies Infectieuses et Tropicales [CHU Raymond Poincaré], Hôpital Raymond Poincaré [AP-HP], Epidémiologie et modélisation de la résistance aux antimicrobiens - Epidemiology and modelling of bacterial escape to antimicrobials (EMAE), Institut Pasteur [Paris] (IP), Unité de Recherche Clinique des hôpitaux Pitié-Salpêtrière – Charles Foix [CHU Pitié Salpêtrière] (URC PSL-CFX), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Direction de la Recherche Clinique et de l'Innovation [AP-HP] (DRCI), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Services de Maladies Infectieuses et Tropicales [CHU Bichat], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Cité - UFR Médecine [Santé] (UPCité UFR Médecine), Université Paris Cité (UPCité), Grand Hôpital de l'Est Francilien (GHEF), Centre Hospitalier René Dubos [Pontoise], Hôpital Beaujon [AP-HP], Hôpital Foch [Suresnes], Service de médecine interne [CHU Ambroise Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Hôpital Ambroise Paré [AP-HP], Hôpital Lariboisière-Fernand-Widal [APHP], Centre Hospitalier de Melun (CHM), CHU Rouen, Normandie Université (NU), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Service de médecine d'urgence [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Centre Hospitalier Princesse Grace, Centre Hospitalier Universitaire [Grenoble] (CHU), Université Grenoble Alpes (UGA), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre Hospitalier de Versailles André Mignot (CHV), Hopital Saint-Louis [AP-HP] (AP-HP), This study was supported by grant PHRC 2005AOM05031 from the French Ministry of Health and sponsored by grant PO50607 from the DRCI of Versailles., HAL UVSQ, Équipe, Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière] (CIC Paris-Est), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), UFR Médecine [Santé] - Université Paris Cité (UFR Médecine UPCité), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Pfizer, Ministère des Affaires Sociales et de la Santé: PO50607, Funding/Support: This study was supported by grant PHRC 2005AOM05031 from the French Ministry of Health and sponsored by grant PO50607 from the DRCI of Versailles., and Conflict of Interest Disclosures: Dr Crémieux reported receiving grants from the French Ministry of Health during the conduct of the study and from Pfizer outside the submitted work. No other disclosures were reported.
Subjects: Male, medicine.medical_specialty, Population, Placebo, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, law.invention, 03 medical and health sciences, 0302 clinical medicine, Community-acquired pneumonia, Randomized controlled trial, law, Risk Factors, Internal medicine, medicine, Humans, 030212 general & internal medicine, Treatment Failure, education, Aged, Original Investigation, Aged, 80 and over, Univariate analysis, education.field_of_study, Duration of Therapy, business.industry, Research, General Medicine, Odds ratio, Pneumonia, Middle Aged, medicine.disease, 3. Good health, Community-Acquired Infections, Hospitalization, Online Only, Infectious Diseases, 030228 respiratory system, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Complication, business
Abstract: Key Points Question What are the risk factors for treatment failure in patients with community-acquired pneumonia (CAP) who reached clinical stability after 3 days of β-lactam treatment? Findings In this secondary analysis of a randomized clinical trial that included 291 adults, only male sex and age were associated with failure in the multivariable analysis. These results were independent of antibiotic treatment duration and biomarker levels. Meaning In this study, among patients with CAP who reached clinical stability after 3 days of antibiotic treatment, male sex and age were associated with higher risk of failure, suggesting that these factors should be taken in account in the treatment of patients with the condition., Importance Failure of treatment is the most serious complication in community-acquired pneumonia (CAP). Objective To assess the potential risk factors for treatment failure in clinically stable patients with CAP. Design, Setting, and Participants This secondary analysis assesses data from a randomized clinical trial on CAP (Pneumonia Short Treatment [PTC] trial) conducted from December 19, 2013, to February 1, 2018. Data analysis was performed from July 18, 2019, to February 15, 2020. Patients hospitalized at 1 of 16 centers in France for moderately severe CAP who were clinically stable at day 3 of antibiotic treatment were included in the PTC trial and analyzed in the per-protocol trial population. Interventions Patients were randomly assigned (1:1) on day 3 of antibiotic treatment to receive β-lactam (amoxicillin-clavulanate [1 g/125 mg] 3 times daily) or placebo for 5 extra days. Main Outcomes and Measures The main outcome was failure at 15 days after first antibiotic intake, defined as a temperature greater than 37.9 °C and/or absence of resolution or improvement of respiratory symptoms and/or additional antibiotic treatment for any cause. The association among demographic characteristics, baseline clinical and biological variables available (ie, at the first day of β-lactam treatment), and treatment failure at day 15 among the per-protocol trial population was assessed by univariate and multivariable logistic regressions. Results Overall, 310 patients were included in the study; this secondary analysis comprised 291 patients (174 [59.8%] male; mean [SD] age, 69.6 [18.5] years). The failure rate was 26.8%. Male sex (odds ratio [OR], 1.74; 95% CI, 1.01-3.07), age per year (OR, 1.03; 95% CI, 1.01-1.05), Pneumonia Severe Index score (OR, 1.01; 95% CI, 1.00-1.02), the presence of chronic lung disease (OR, 1.85; 95% CI, 1.03-3.30), and creatinine clearance (OR, 0.99; 95% CI, 0.98-1.00) were significantly associated with failure in the univariate analysis. When the Pneumonia Severe Index score was excluded to avoid collinearity with age and sex in the regression model, only male sex (OR, 1.92; 95% CI, 1.08-3.49) and age (OR, 1.02; 95% CI, 1.00-1.05) were associated with failure in the multivariable analysis. Conclusions and Relevance In this secondary analysis of a randomized clinical trial, among patients with CAP who reached clinical stability after 3 days of antibiotic treatment, only male sex and age were associated with higher risk of failure, independent of antibiotic treatment duration and biomarker levels. Another randomized clinical trial is needed to evaluate the impact of treatment duration in populations at higher risk for treatment failure., This secondary analysis of a randomized clinical trial assesses treatment failure risk factors in patients with community-acquired pneumonia who reached clinical stability after 3 days of β-lactam treatment.
Published: 2021
Full Text: View/download PDF

6. The spectrum of biochemical alterations associated with organ dysfunction and inflammatory status and their association with disease outcomes in severe COVID-19: A longitudinal cohort and time-series design study

Author: Beatrice Maatem Caillierez, Elodie Laugel, Isabelle Aimone-Gastin, Sophie Orlowski, Nathalie Thilly, Bruno Levy, F Barbé, Evelyne Schvoerer, Sébastien Gibot, Luc Frimat, Sybille Bevilacqua, Abderrahim Oussalah, Marie Reine Losser, Antoine Kimmoun, Stanislas Gleye, Jean-Louis Guéant, Marc Merten, Rosa Maria Rodriguez-Gueant, Farès Namour, Isabelle Clerc Urmes, Raphaël Kormann, Elise Jeannesson, Jean Luc Olivier, Catherine Malaplate, Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Biochimie – Biologie moléculaire et Nutrition [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Unité de Méthodologie, Data Managment et Statistiques, Département Méthodologie, Promotion, Investigation (DMPI), Délégation à la Recherche Clinique et à l'Innovation (DRCI), [CHRU Nancy], Service de Virologie [CHRU Nancy], Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement (LCPME), Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de Néphrologie [CHRU Nancy], Composés Alimentaires : Biofonctionnalités et risques Neurotoxiques (CALBINOTOX), Université de Lorraine (UL), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Service d'Anesthésiologie et de Soins Intensifs [CHRU Nancy], Service de Soins Intensifs [CHRU Nancy], Délégation à la Recherche Clinique et à l'Innovation [CHRU Nancy] (DRCI), and CCSD, Accord Elsevier
Subjects: medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), 01 natural sciences, Gastroenterology, Article, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, medicine, 030212 general & internal medicine, 0101 mathematics, Stage (cooking), ComputingMilieux_MISCELLANEOUS, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, lcsh:R5-920, Kidney, Lung, business.industry, 010102 general mathematics, Organ dysfunction, Acute kidney injury, General Medicine, Odds ratio, medicine.disease, 3. Good health, medicine.anatomical_structure, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, medicine.symptom, lcsh:Medicine (General), Pancreas, business
Abstract: International audience; Background: In patients with severe COVID-19, no data are available on the longitudinal evolution of biochemical abnormalities and their ability to predict disease outcomes.Methods: Using a retrospective, longitudinal cohort study design on consecutive patients with severe COVID-19, we used an extensive biochemical dataset of serial data and time-series design to estimate the occurrence of organ dysfunction and the severity of the inflammatory reaction and their association with acute respiratory failure (ARF) and death.Findings: On the 162 studied patients, 1151 biochemical explorations were carried out for up to 59 biochemical markers, totaling 15,260 biochemical values. The spectrum of biochemical abnormalities and their kinetics were consistent with a multi-organ involvement, including lung, kidney, heart, liver, muscle, and pancreas, along with a severe inflammatory syndrome. The proportion of patients who developed an acute kidney injury (AKI) stage 3, increased significantly during follow-up (0·9%, day 0; 21·4%, day 14; P250 iterations), only CRP >90 mg/L (odds ratio [OR] 6·87, 95% CI, 2·36-20·01) and urea nitrogen >0·36 g/L (OR 3·91, 95% CI, 1·15-13·29) were independently associated with the risk of ARF. Urea nitrogen >0·42 g/L was the only marker associated with the risk of COVID-19 related death.Interpretation: Our results point out the lack of the association between the inflammatory markers and the risk of death but rather highlight a significant association between renal dysfunction and the risk of COVID-19 related acute respiratory failure and death.
Published: 2020
Full Text: View/download PDF

7. Dietary Fibres and the Management of Obesity and Metabolic Syndrome: The RESOLVE Study

Author: Bruno Lesourd, Bruno Pereira, Angelo Tremblay, Maëlys Clinchamps, David Thivel, Vicky Drapeau, Julien Simon Baker, Elodie Chaplais, Guillaume Walther, Philippe Obert, Reza Bagheri, Robert Chapier, Agnès Vinet, Frédéric Dutheil, Daniel Courteix, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques - Clermont Auvergne (AME2P), Faculté des Sciences du SportFaculté des Sciences du Sport, UFR STAPS-Université Clermont Auvergne (UCA), Department of Kinesiology, Université Laval, Quebec City, QC G1V 0A6, Canada, Preventive and Occupational Medicine, University Hospital of Clermont-Ferrand, 63000 Clermont-Ferrand, France, service de Biostatistiques, DRCI, Centre Hospitalier Universitaire de Clermont-Ferrand, Thermalia Center, F-63140 Châtelguyon, France, EA4278 Laboratoire de Pharm-Ecologie Cardiovasculaire (LaPEC), Avignon Université (AU), Développement, Adaptation et Handicap. Régulations cardio-respiratoires et de la motricité. (DevAH), Université de Lorraine (UL), Institut sur la Nutrition et les Aliments Fonctionnels [université Laval, Québec] (INAF), Université Laval [Québec] (ULaval), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne (UCA)-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Développement, Adaptation et Handicap. Régulations cardio-respiratoires et de la motricité (DevAH), Department of Exercise Physiology, University of Isfahan, Isfahan 81746-73441, Iran, Centre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong 999077, Hong Kong, Physical Institut, Universitaire de France, 75000 Paris, France, WittyFit, Laboratoire de Psychologie Sociale et Cognitive (LAPSCO), and Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)
Subjects: Dietary Fiber, Male, Diet, Reducing, macronutrient, 030209 endocrinology & metabolism, lcsh:TX341-641, 030204 cardiovascular system & hematology, Body weight, Weight Reduction Program, Management of obesity, Article, 03 medical and health sciences, Fiber intake, body weight, 0302 clinical medicine, Animal science, Weight Loss, Macronutrient composition, Medicine, Humans, Obesity, Aged, 2. Zero hunger, Metabolic Syndrome, Dietary fibres, Nutrition and Dietetics, exercise, business.industry, Nutrients, Middle Aged, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, medicine.disease, Body Composition, Dietary fiber, Female, sense organs, Metabolic syndrome, business, Energy Intake, Energy Metabolism, diet, lcsh:Nutrition. Foods and food supply, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Food Science
Abstract: Objectives: This study was performed to evaluate the long-term maintenance of nutritional changes promoted during an intensive initial intervention to induce body weight loss. The ability of these changes to predict long-term health outcomes was also examined. Methods: Nutritional variables, body composition, and metabolic markers collected in the RESOLVE project were analyzed before and after a 3-week intensive diet&ndash, exercise intervention (Phase 1), and during a subsequent supervision under free living conditions, of 12 months (Phase 2). Results: As expected, the macronutrient composition of the diet was modified to promote a negative energy balance during Phase 1. The decrease in carbohydrates imposed during this phase was maintained during Phase 2 whereas the increase in protein intake returned to baseline values at the end of the program. Dietary fiber intake was almost doubled during Phase 1 and remained significantly greater than baseline values throughout Phase 2. Moreover, fiber intake was the only nutritional variable that systematically and significantly predicted variations of health outcomes in the study. Conclusion: The adequacy of dietary fiber intake should be a matter of primary consideration in diet-based weight reduction programs.
Published: 2020
Full Text: View/download PDF

8. Delayed meal timing after exercise is associated with reduced appetite and energy intake in adolescents with obesity

Author: Valérie Julian, Yves Boirie, Graham Finlayson, Mélina Bailly, David Thivel, Bruno Pereira, Maud Miguet, Martine Duclos, Alicia Fillon, Kristine Beaulieu, Julie Masurier, Service Médecine du Sport et Explorations Fonctionnelles [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Psychology, University of Konstanz, Inst Psychol Sci, Biopsychol Grp, University of Leeds, CRNH Auvergne, SSR Nutrition Obésité, service de Biostatistiques, DRCI, Unité de Nutrition Humaine (UNH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de Nutrition Clinique [CHU Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Nutrition Obesity Ambulatory Hospital (UGECAM), Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), and Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI)
Subjects: 0301 basic medicine, Adult, Male, Pediatric Obesity, Time Factors, Hunger, media_common.quotation_subject, [SDV]Life Sciences [q-bio], education, Energy balance, 030209 endocrinology & metabolism, Satiation, 03 medical and health sciences, 0302 clinical medicine, Animal science, Reward, medicine, Humans, Beneficial effects, Exercise, Meals, ComputingMilieux_MISCELLANEOUS, media_common, obesity, 2. Zero hunger, Meal, 030109 nutrition & dietetics, Nutrition and Dietetics, business.industry, Health Policy, digestive, oral, and skin physiology, Public Health, Environmental and Occupational Health, Appetite, Before Dinner, medicine.disease, Obesity, food reward, Reduced appetite, appetite, adolescent, Pediatrics, Perinatology and Child Health, exercise timing, energy intake, Female, business, Energy Metabolism, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Background: While the beneficial effects of exercise on appetite might depend on its timing during the day or relative to a meal, this remains poorly explored in youth.Objectives: To examine the importance of meal timing (+30 vs +90 minutes) after performing exercise on energy intake, appetite and food reward in adolescents with obesity.Methods: Eighteen adolescents with obesity randomly completed three conditions: (a) lunch (12:00 pm) set 30 minutes after a rest session (11:00 am); (b) lunch (12:00 pm) set 30 minutes after an exercise session (11:00 am)(MEAL-30); (c) lunch (01:00 pm) set 90 minutes after an exercise session (11:00 am)(MEAL-90). Lunch and dinner ad libitum energy intake was assessed, food reward (LFPQ) assessed before and after lunch, and before dinner, appetite sensations were assessed at regular intervals.Results: Energy intake was lower at MEAL-90 than MEAL-30 and CON at lunch (P < .05 and P < .01, respectively) and lunch + dinner combined (P < .001). A decrease in intake (g) of protein, fat and carbohydrate was observed. Post-exercise hunger was lower on MEAL-90 compared with CON. No condition effects were found at lunch for food reward.Conclusions: Delaying the timing of the meal after exercise might help affect energy balance by decreasing ad libitum energy intake without increasing hunger and by improving satiety in adolescents with obesity.
Published: 2020
Full Text: View/download PDF

9. Does exercising before or after a meal affect energy balance in adolescents with obesity?

Author: Bruno Pereira, David Thivel, Valérie Julian, Yves Boirie, Martine Duclos, Graham Finlayson, Mélina Bailly, Kristine Beaulieu, Julie Masurier, Alicia Fillon, Maud Miguet, Marie-Eve Mathieu, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Faculty of Medicine and Health, CRNH Auvergne, Centre de SSR Nutrition-Obésité UGECAM, Research Centre of the Sainte-Justine University Hospital, service de Biostatistiques, DRCI, CHU Clermont-Ferrand, Unité de Nutrition Humaine (UNH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), UGECAM, Service Médecine du Sport et Explorations Fonctionnelles [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Estaing [Clermont-Ferrand], Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre de recherche du CHU Sainte-Justine / Research Center of the Sainte-Justine University Hospital [Montreal, Canada], and Université de Montréal (UdeM)-CHU Sainte Justine [Montréal]
Subjects: Male, Pediatric Obesity, Time Factors, Endocrinology, Diabetes and Metabolism, [SDV]Life Sciences [q-bio], Energy balance, Child Behavior, Medicine (miscellaneous), Appetite, 030204 cardiovascular system & hematology, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Medicine, Child, ComputingMilieux_MISCELLANEOUS, media_common, Meal, Nutrition and Dietetics, digestive, oral, and skin physiology, Age Factors, Postprandial Period, Female, France, Cardiology and Cardiovascular Medicine, Exercise-meal timing, medicine.medical_specialty, Adolescent, media_common.quotation_subject, 030209 endocrinology & metabolism, Affect (psychology), Food preference, 03 medical and health sciences, Reward, Humans, Obesity, Exercise, Beneficial effects, Appetite Regulation, business.industry, Food reward, Feeding Behavior, medicine.disease, Bicycling, Adolescent Behavior, Physical therapy, Energy intake, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background and aim Exercise timing has been suggested to affect appetite and energy intake (EI). The aim of this study was to examine the impact of exercising immediately before or after a meal on EI, appetite sensations and food reward (FR) in adolescents with obesity. Methods and results Seventeen adolescents with obesity completed 3 experimental sessions (randomized controlled trial): rest + lunch (CON); exercise + lunch (EX-MEAL); lunch + exercise (MEAL-EX). The exercise consisted of cycling 30 min at 65%V̇O2peak. Outcomes included ad libitum EI (weighed lunch and dinner), FR (Leeds Food Preference Questionnaire at pre- and post-combination of exercise/rest and lunch, and pre-dinner) and appetite sensations (visual analogue scales). EI was not different between conditions. Compared with CON, relative EI at lunch was lower in EX-MEAL and MEAL-EX (p ≤ 0.05) and daily only in MEAL-EX (p < 0.01). Postprandial fullness was higher in EX-MEAL compared to CON. Compared with CON, both EX-MEAL and MEAL-EX attenuated the increase in wanting for sweet food and reduced explicit liking for fat. Conclusions These preliminary results suggest that exercising immediately before or after a meal produce few differences in appetite and have small beneficial effects on overall energy balance in adolescents with obesity, as well as on FR. Clinical trials NCT03967782.
Published: 2020
Full Text: View/download PDF

10. Muscle function and architecture in children with juvenile idiopathic arthritis

Author: Frédéric Dutheil, Bruno Pereira, Pascale Duché, Sébastien Ratel, Anthony Birat, Emmanuelle Rochette, Etienne Merlin, Daniel Courteix, Eric Doré, Pierre Bourdier, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CIC Clermont Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-Centre de Pharmacologie Clinique, CHU Clermont-Ferrand, Impact de l'Activité Physique sur la Santé (IAPS), Université de Toulon (UTLN), Laboratoire de Psychologie Sociale et Cognitive (LAPSCO), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Service Santé Travail Environnement [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, WittyFit, Australian Catholic University (ACU), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques - Clermont Auvergne (AME2P), Faculté des Sciences du SportFaculté des Sciences du Sport, UFR STAPS-Université Clermont Auvergne (UCA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Pharmacologie Clinique-CHU Gabriel-Montpied, Laboratoire de Psychologie Sociale et Cognitive - Clermont Auvergne (LAPSCO), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), School of Exercise Science [Melbourne, VIC, Australia] (Faculty of Health), Délégation à la recherche clinique et aux innovations (DRCI), CHU de Clermont-Ferrand, CIC - Clermont Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Université Clermont Auvergne (UCA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and LAPSCO, HAL
Subjects: musculoskeletal diseases, medicine.medical_specialty, [SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Arthritis, intermuscular adipose tissue, Isometric exercise, Growth, 03 medical and health sciences, Vertical jump, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, 0302 clinical medicine, IMAT, Internal medicine, medicine, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Quantitative computed tomography, Child, Muscle, Skeletal, ComputingMilieux_MISCELLANEOUS, Ultrasonography, 030203 arthritis & rheumatology, Inflammation, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, medicine.diagnostic_test, business.industry, Ultrasound, Paediatrics, 030229 sport sciences, General Medicine, Fascicle, medicine.disease, Arthritis, Juvenile, Physical activity level, Peripheral, Adipose Tissue, Pediatrics, Perinatology and Child Health, Cardiology, [SDV.IMM]Life Sciences [q-bio]/Immunology, Muscle, Tomography, X-Ray Computed, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Aim: To assess muscle function and functional abilities in children with juvenile idiopathic arthritis (JIA). Methods: Fourteen children with JIA and 14 healthy controls matched for age and sex were included. Muscle characteristics, both structural (thickness, cross-sectional area (CSA) and fascicle angle) and qualitative (intermuscular adipose tissue : IMAT) were assessed on thigh muscles using ultrasound and peripheral quantitative computed tomography (pQCT). Muscle function and functional abilities were determined from the assessment of maximal voluntary isometric contraction force (MVIC) of the knee extensors and vertical jump performance. Results: No significant difference in MVIC force was observed between both groups. However, squat jump height was significantly reduced in children with JIA (18.3 ± 5.4 vs 24.3 ± 7.9 cm, p
Published: 2020
Full Text: View/download PDF

11. Serum soluble receptor for advanced glycation end-products during acute bronchiolitis in infant: Prospective study in 93 cases

Author: Karen Coste, Emmanuelle Rochette, Aurélien Mulliez, Matthieu Jabaudon, Vincent Sapin, Laurence Roszyk, André Labbé, Carole Egron, CHU Clermont-Ferrand, Pôle Pédiatrie, Centre Hospitalier Universitaire [Rennes], Génétique, Reproduction et Développement (GReD), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Medical Biochemistry and Molecular Biology, CHU Clermont-Ferrand, Délégation à la recherche clinique et aux innovations (DRCI), CHU de Clermont-Ferrand, Laboratoires d'Anatomie pathologique et de Physiologie, Université d'Auvergne - Clermont-Ferrand I (UdA), Faculté de Médecine - Clermont-Auvergne (FM - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service de Biochimie et Génétique Moléculaire [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], Génétique, Reproduction et Développement (GReD ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Laboratoire de Biochimie, Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Estaing [Clermont-Ferrand], and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, 0301 basic medicine, ARDS, MESH: Respiratory Sounds, Receptor for Advanced Glycation End Products, MESH: Bronchiolitis, Infection and Immunity, MESH: Hospitalization, Severity of Illness Index, Gastroenterology, Pathogenesis, 0302 clinical medicine, Recurrence, Prospective Studies, Respiratory system, soluble receptor for advanced glycation end-products, Prospective cohort study, ComputingMilieux_MISCELLANEOUS, blood and urine biomarkers, infants, Prognosis, MESH: Infant, 3. Good health, Hospitalization, Acute Disease, Bronchiolitis, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: Acute Disease, Biomarker (medicine), Female, Original Article, Pulmonary and Respiratory Medicine, medicine.medical_specialty, [SDV.BDLR.RA]Life Sciences [q-bio]/Reproductive Biology/Asexual reproduction, MESH: Prognosis, [SDV.BDLR.RS]Life Sciences [q-bio]/Reproductive Biology/Sexual reproduction, 03 medical and health sciences, soluble receptor for advanced glycation end‐products, recurrent wheezing, MESH: Severity of Illness Index, Internal medicine, Lower respiratory tract infection, medicine, Humans, Respiratory Sounds, Asthma, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, MESH: Humans, MESH: Receptor for Advanced Glycation End Products, business.industry, Infant, Original Articles, medicine.disease, MESH: Male, MESH: Prospective Studies, MESH: Recurrence, 030104 developmental biology, 030228 respiratory system, Pediatrics, Perinatology and Child Health, MESH: Biomarkers, lower respiratory tract infection, business, MESH: Female, Biomarkers, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Introduction Acute bronchiolitis is a major cause of acute respiratory distress in infants. The soluble receptor for advanced glycation end‐products (sRAGE) is a biomarker of pulmonary damage processes, with a diagnostic and a prognostic value in acute respiratory distress syndrome (ARDS). The RAGE pathway is also implicated in the pathogenesis of other respiratory diseases like asthma, but the value of sRAGE levels in acute bronchiolitis remains under‐investigated. Material and methods A prospective, observational, and analytical study was conducted at Clermont‐Ferrand University Hospital. The main objective was to evaluate the correlation between serum sRAGE and clinical severity of bronchiolitis in hospitalized infants aged
Published: 2018
Full Text: View/download PDF

12. Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients

Author: Marine Freist, Elodie Gentes, Carole Philipponnet, Mohamed Hadj Abdelkader, Bruno Pereira, Aurélien Piraud, Cyril Garrouste, Anne-Elisabeth Heng, Julien Aniort, Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Emile Roux [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Néphrologie - Hémodialyses [CHU Clermont-Ferrand], Pôle RHEUNNIRS [CHU Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Dept Clin Nutr, Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Unité de Biostatistiques, Direction de la Recherche Clinique (DRCI)
Subjects: Male, 0301 basic medicine, dialyse, [SDV]Life Sciences [q-bio], medicine.medical_treatment, 030232 urology & nephrology, Muscle Proteins, Biochemistry, protéasome, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Gastroenterology, 0302 clinical medicine, Medicine and Health Sciences, 2. Zero hunger, Multidisciplinary, Protein energy wasting, Muscle Analysis, Middle Aged, C-Reactive Proteins, Muscle atrophy, atrophie musculaire, 3. Good health, Hospitalization, Bioassays and Physiological Analysis, Nephrology, Creatinine, Medicine, Female, patient, Hemodialysis, medicine.symptom, Research Article, Proteasome Endopeptidase Complex, medicine.medical_specialty, Science, Nutritional Status, Circulating Proteasome, Research and Analysis Methods, Protein-Energy Malnutrition, 03 medical and health sciences, Signs and Symptoms, Renal Dialysis, Internal medicine, Medical Dialysis, medicine, Humans, Mortality, Survival rate, Nutrition, Aged, Wasting Syndrome, business.industry, Biology and Life Sciences, Proteins, Protein Complexes, Proteasomes, medicine.disease, perte d'énergie, Patient Outcome Assessment, 030104 developmental biology, Proteasome, Clinical Medicine, Atrophy, Complication, business, Biomarkers, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Kidney disease
Abstract: International audience; Protein energy wasting (PEW) including muscle atrophy is a common complication in chronic hemodialysis patients. The ubiquitin proteasome system (UPS) is the main proteolytic system causing muscle atrophy in chronic kidney disease and proteasome 20S is the catalytic component of the UPS. Circulating proteasome 20S (c20S proteasome) is present in the blood and its level is related to disease severity and prognosis in several disorders. We hypothesized that c20S proteasome could be related with muscle mass, other PEW criteria and their evolution in hemodialysis patients. Stable hemodialysis patients treated at our center for more than 3 months were followed over 2 years. C20S proteasome assay was performed at baseline. Biological and clinical data were collected, muscle mass was assessed by multi-frequency bio-impedancemetry, and nutritional scores were calculated at baseline, 1 year and 2 years. Hospitalizations and mortality data were collected over the 2 years. Forty-nine patients were included. At baseline, the c20S proteasome level was 0.40 [0.26-0.55] mu g/ml. Low muscle mass as defined by a lean tissue index (LTI) < 10th in accordance with the International Society of Renal Nutrition and Metabolism guidelines was observed in 36% and PEW in 62%. Increased c20S proteasome levels were related with LTI at baseline (R = 0.43, p = 0.004) and with its 2 year-variation (R = -0.56, p = 0.003). Two-year survival rate was not different between higher and lower c20S proteasome values (78.9 vs 78.4%, p = 0.98 log-rank test). C20S proteasome is not a good marker for assessing nutritional status in hemodialysis patients and predicting patient outcomes.
Published: 2020
Full Text: View/download PDF

13. Bone response to eccentric versus concentric cycling in adolescents with obesity

Author: Daniel Courteix, Valérie Julian, Martine Duclos, David Thivel, Chloé Brengues, Ruddy Richard, Maud Miguet, Bruno Pereira, Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), service de Biostatistiques, DRCI, CHU Clermont-Ferrand, Médecine du Sport et Explorations Fonctionnelles, Université d'Auvergne - Clermont-Ferrand I (UdA), Unité de Nutrition Humaine (UNH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and CRNH Auvergne
Subjects: 0301 basic medicine, medicine.medical_specialty, Adolescent, Bone density, genetic structures, Endocrinology, Diabetes and Metabolism, Concentric training, 030209 endocrinology & metabolism, Bone strength, Childhood obesity, Body Mass Index, 03 medical and health sciences, Absorptiometry, Photon, Oxygen Consumption, 0302 clinical medicine, Weight loss, Bone mineral density, Humans, Medicine, Eccentric, Obesity, 2. Zero hunger, 030109 nutrition & dietetics, Nutrition and Dietetics, Anthropometry, business.industry, medicine.disease, Eccentric training, Lean body mass, Physical therapy, sense organs, medicine.symptom, business, Body mass index, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Objectives: Because adolescents with obesity are susceptible to bone fragility during weight loss (WL), we evaluated the impact of eccentric (ECC) versus classical concentric (CON) training at the same oxygen consumption (V˙O2) on bone density, geometry and strength.Methods: Thirty five adolescents were included into 2 training (CON and ECC cycling) and a control (CTR, without training) groups. Anthropometry, dual-energy X-ray absorptiometry, hip structural analysis and quantitative bone ultrasound were assessed before and after the 12-week intervention.Results: The trainings promoted significant improvements in body mass index, total fat (FM) and lean mass (LM), with better improvements for FM and LM in the ECC group (p < 0.05). Leg LM percentage increased only in the ECC group (p < 0.05). Total body bone mineral content and density increased in both training groups (p < 0.001) with significant time x group interactions only between ECC and CTR (p < 0.05). Buckling ratio at the intertrochanteric region and femoral shaft increased only in CTR and CON groups (p < 0.05). Speeds of sounds at the calcaneum increased only in ECC group (p < 0.01).Conclusions: Bone fragility, from a compromised relationship between density, geometry and strength, might be prevented with the ECC modality.
Published: 2020
Full Text: View/download PDF

14. Predicting Pain Trajectories in the One Year Following Breast Cancer Diagnosis—An Observational Study

Author: Christine Villatte, Elodie Martin, Véronique Morel, Bruno Pereira, Dominique Joly, Xavier Durando, Gisèle Pickering, Marion Voute, COLO, Mouniati, Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand, Neuro-Dol (Neuro-Dol), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)
Subjects: medicine.medical_specialty, predictive profile, [SDV]Life Sciences [q-bio], lcsh:Medicine, [SDV.CAN]Life Sciences [q-bio]/Cancer, psychosocial vulnerability, Article, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, breast cancer, Quality of life, pain trajectories, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Prospective cohort study, skin and connective tissue diseases, business.industry, Large effect size, Significant difference, lcsh:R, Cancer, General Medicine, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, Observational study, business, Psychosocial, 030217 neurology & neurosurgery
Abstract: The impact of psychosocial vulnerability on pain in the year following breast cancer diagnosis has been little studied. To identify a score of psychosocial vulnerability (cognitive, emotional, quality of life and precariousness parameters) as a predictor of a pain trajectory, we conducted an observational prospective study and included women with newly diagnosed breast cancer. One year follow-up with 3 visits (day of breast cancer diagnosis, 6 and 12 months) aimed to identify distinct pain-time trajectories. Baseline psychosocial vulnerability was characterized by z-score transformation, a higher score representing a more vulnerable patient. A total of 89 patients were included (59.3 &plusmn, 10.7 years). Two trajectories of pain were identified&mdash, &ldquo, Transient Pain trajectory&rdquo, (TP) (39/89 patients) and &ldquo, Persistent Pain trajectory&rdquo, (PP) (50/89). A significant difference of pain over time between trajectories (PP vs. TP at 6 months: 2.23 &plusmn, 0.23 vs. 0.27 &plusmn, 0.09, p &lt, 0.001) was observed. Psychosocial vulnerability showed a large effect size (d, &minus, 0.82, 95% CI, &minus, 1.25 to &minus, 0.38, p &lt, 0.001) and a higher score in &ldquo, Persistent pain trajectory&rdquo, (PP vs. TP: 0.12 &plusmn, 0.36 vs. &minus, 0.14 &plusmn, 0.26, p &lt, 0.001). A predictive vulnerability marker of pain development is proposed and could be used at cancer diagnosis to orientate the care pathway of patients experiencing breast cancer.
Published: 2020
Full Text: View/download PDF

15. Stress management in obesity during a thermal spa residential programme (ObesiStress): protocol for a randomised controlled trial study

Author: Yves Boirie, Daniela M. Pfabigan, Omar Izem, Magalie Miolanne-Debouit, N. Farigon, Bruno Pereira, Laurie Mobdillon, Guillaume T. Vallet, Armand Abergel, Pascale Duché, Gil Boudet, Philippe Obert, Shihui Han, Elodie Chaplais, Daniel Courteix, Frédéric Dutheil, Audrey Vilmant, Martial Mermillod, Laboratoire de Psychologie Sociale et Cognitive - Clermont Auvergne (LAPSCO), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), Institut de Médecine du Travail, CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I (UdA), Laboratoire Développement, Adaptation et Handicap (DevAH), Unité de Biostatistiques [CHU Clermont-Ferrand] (Département de la recherche clinique et de l'innovation - DRCI), CHU Clermont-Ferrand, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Faculté des Sciences du SportFaculté des Sciences du Sport, UFR STAPS, Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Impact de l'Activité Physique sur la Santé (IAPS), Université de Toulon (UTLN), Service d'Hépato-Gastroentérologie [CHRU Clermont-Ferrand], Centre Hospitalier Universitaire de Clermont-Ferrand, Peking University [Beijing], PKU-IDG/McGovern Institute For Brain Research, Centre de recherche en économie de Grenoble (CREG), Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Grenoble Alpes (UGA), Institut Universitaire de France (IUF), Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.), Physiopathologie des adaptations cardiovasculaires à l'Exercice, Avignon Université (AU), EA4278 Laboratoire de Pharm-Ecologie Cardiovasculaire (LaPEC), Nutrition clinique, Centre Hospitalier Universitaire Gabriel Montpied, nutrition clinique, Unité de Nutrition Humaine (UNH), Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université, Université Clermont Auvergne (UCA), Centre National de la Recherche Scientifique (CNRS), Service Santé Travail Environnement, EA 3450, Université de Lorraine (UL), Département Recherche Clinique et Innovation, EA 3533, Laboratoire des Adaptations Métaboliques à l’Exercice en conditions Physiologiques et Pathologiques (AME2P), Laboratoire Impact de l’Activité Physique sur la Santé, Hépatologie Gastro-Entérologie, Centre Hospitalier Universitaire Estaing, UMR 6284, University Beijing, Laboratoire de Psychologie et NeuroCognition (LPNC), Université Grenoble Alpes (COMUE) (UGA), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), EA 4278, laboratoire de Pharm-Ecologie Cardiovasculaire (LaPEC ), Biostatistiques, Danone Research, Unité de Nutrition Humaine - Clermont Auvergne (UNH), Université Clermont Auvergne (UCA)-Institut National de la Recherche Agronomique (INRA), Laboratoire de Psychologie Sociale et Cognitive (LAPSCO), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Développement, Adaptation et Handicap. Régulations cardio-respiratoires et de la motricité (DevAH), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Ferrand (UFR STAPS - UBP), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP), Service d'Hépatologie Gastro-entérologie [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Auvergne Rhone-Alpes University Hospital of Clermont-Ferrand European Regional Development Fund (Fonds Europeen de Developpement Economique et Regional), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Ferrand (UFR STAPS - UBP), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP), and Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA)
Subjects: musculoskeletal diseases, Stress management, medicine.medical_specialty, obesity, Cardiovascular Medicine, Overweight, Body Mass Index, law.invention, 03 medical and health sciences, stress, 0302 clinical medicine, Quality of life, Randomized controlled trial, prevention, Heart Rate, law, Protocol, Humans, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Randomized Controlled Trials as Topic, 2. Zero hunger, business.industry, Public health, heart rate variability, Hyperthermia, Induced, General Medicine, Anthropometry, medicine.disease, Obesity, 3. Good health, spa bath, Body Composition, Quality of Life, Physical therapy, France, medicine.symptom, business, Body mass index, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Biomarkers, Stress, Psychological, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: IntroductionStress and obesity are two public health issues. The relationship between obesity and stress is biological through the actions of stress on the major hormones that regulate appetite (leptin and ghrelin). Many spa resorts in France specialise in the treatment of obesity, but no thermal spa currently proposes a specific programme to manage stress in obesity. The ObesiStress protocol has been designed to offer a new residential stress management programme. This thermal spa treatment of obesity implements stress management strategies as suggested by international recommendations.Methods and analysis140 overweight or obese participants with a Body Mass Index of >25 kg/m2 and aged over 18 years will be recruited. Participants will be randomised into two groups: a control group of usual practice (restrictive diet, physical activity and thermal spa treatment) and an intervention group with stress management in addition to the usual practice. In the present protocol, parameters will be measured on five occasions (at inclusion, at the beginning of the spa (day 0), at the end of the spa (day 21), and at 6 and 12 months). The study will assess the participants’ heart rate variability, cardiac remodelling and function, electrodermal activity, blood markers, anthropometric profile, body composition, psychology and quality of life via the use of questionnaires and bone parameters.Ethics and disseminationThe ObesiStress protocol complies with the ethics guidelines for Clinical Research and has been approved by the ethics committee (CPP Sud-Est VI, Clermont-Ferrand - ANSM: 2016-A01774-47). This study aimed to highlight the efficacy of a 21-day thermal spa residential programme of stress management in obesity through objective measurements of well-being and cardiovascular morbidity. Results will be disseminated during several research conferences and articles published in peer-reviewed journals.Trial registration numberNCT03578757.
Published: 2019
Full Text: View/download PDF

16. Post-moderate-intensity exercise energy replacement does not reduce subsequent appetite and energy intake in adolescents with obesity

Author: Alicia Fillon, Yves Boirie, David Thivel, Marwa Khammassi, Masashi Miyashita, Graham Finlayson, Julie Masurier, Alice E. Thackray, Martine Duclos, Kristine Beaulieu, Johanna Roche, Maud Miguet, Bruno Pereira, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CRNH Auvergne, Centre de SSR Nutrition-Obésité UGECAM, Psychology, University of Konstanz, University of Leeds, Biostatistiques (DRCI), CHU Clermont-Ferrand, Faculty of Sport Sciences, Waseda University, School of Sport, Exercise and Health Sciences, Loughborough University, Unité de Nutrition Humaine (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Médecine du Sport & Explorations Fonctionnelles, Centre de Recherche en Nutrition Humaine, Nutrition Clinique, Thivel, D., EA 3533, Laboratoire des Adaptations Métaboliques à l’Exercice en conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne (UCA), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Centre Hospitalier Universitaire de Clermont-Ferrand, Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, and Waseda University [Tokyo, Japan]
Subjects: 0301 basic medicine, Energy Replacement, Male, Food intake, Pediatric Obesity, Evening, Adolescent, media_common.quotation_subject, Medicine (miscellaneous), Appetite, 030209 endocrinology & metabolism, Satiation, Adolescents, 03 medical and health sciences, 0302 clinical medicine, Animal science, Exercise, Obesity, medicine, Food and Nutrition, Humans, Energy deficit, Child, media_common, 2. Zero hunger, 030109 nutrition & dietetics, Nutrition and Dietetics, business.industry, digestive, oral, and skin physiology, medicine.disease, Adaptation, Physiological, Intensity (physics), Bicycling, Positive energy, Treatment Outcome, Energy expenditure, Alimentation et Nutrition, Female, business, Energy Intake, Energy Metabolism, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
Abstract: Exercise modifies energy intake (EI) in adolescents with obesity, but whether this is mediated by the exercise-induced energy deficit remains unknown. The present study examined the effect of exercise with and without dietary replacement of the exercise energy expenditure on appetite, EI and food reward in adolescents with obesity. Fourteen 12–15-year-old adolescents with obesity (eight girls; Tanner 3–4; BMI 34·8 (sd 5·7) kg/m2; BMI z score 2·3 (sd 0·4)) randomly completed three experimental conditions: (i) rest control (CON); (ii) 30-min cycling (EX) and (iii) 30-min cycling with dietary energy replacement (EX + R). Ad libitum EI was assessed at lunch and dinner, and food reward (Leeds Food Preference Questionnaire) before and after lunch. Appetite was assessed at regular intervals. Lunch, evening and total EI (excluding the post-exercise snack in EX − R) were similar across conditions. Lunch and total EI including the post-exercise snack in EX + R were higher in EX − R than CON and EX; EX and CON were similar. Total relative EI was lower in EX (6284 (sd 2042) kJ) compared with CON (7167 (sd 2218) kJ; P < 0·05) and higher in EX + R (7736 (sd 2033) kJ) compared with CON (P < 0·001). Appetite and satiety quotients did not differ across conditions (P ≥ 0·10). Pre-meal explicit liking for fat was lower in EX compared with CON and EX + R (P = 0·05). There was time by condition interaction between EX and CON for explicit wanting and liking for fat (P = 0·01). Despite similar appetite and EI, adolescents with obesity do not adapt their post-exercise food intake to account for immediate dietary replacement of the exercise-induced energy deficit, favouring a short-term positive energy balance.
Published: 2019
Full Text: View/download PDF

17. Long-term effects of high-intensity resistance and endurance exercise on plasma leptin and ghrelin in overweight individuals: the RESOLVE Study

Author: Julien Verney, Bruno Pereira, Phillippe Obert, Frédéric Dutheil, Agnès Vinet, Vicky Drapeau, Bruno Lesour, Robert Chapier, Guillaume Walther, Daniel Courteix, Julien S. Baker, Lore Metz, Angelo Tremblay, David Thivel, Institut sur la Nutrition et les Aliments Fonctionnels [université Laval, Québec] (INAF), Université Laval [Québec] (ULaval), Département de Kinésiologie, Université de Montréal, Laval, Québec, Canada, Laboratoire de Psychologie Sociale et Cognitive (LAPSCO), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Service Santé Travail Environnement [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, WittyFit, School of Exercise Science [Melbourne, VIC, Australia] (Faculty of Health), Australian Catholic University (ACU), Department of Physical Education, Université Laval, Québec., Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand, Thermalia Center, F-63140 Châtelguyon, France, Unité de Biostatistiques, Direction de la Recherche Clinique (DRCI), Institute of Clinical Exercise and Health Sciences, School of Science and Sport, University of the West of Scotland, Hamilton, Lanarkshire G72 0BN, Scotland, UK, EA4278 Laboratoire de Pharm-Ecologie Cardiovasculaire (LaPEC), and Avignon Université (AU)
Subjects: Leptin, Male, medicine.medical_specialty, obesity, Physiology, Endocrinology, Diabetes and Metabolism, physical activity, 030209 endocrinology & metabolism, Overweight, 03 medical and health sciences, 0302 clinical medicine, Endurance training, Physiology (medical), Internal medicine, Weight Loss, medicine, Humans, 030212 general & internal medicine, Exercise, Aged, Nutrition and Dietetics, hormones, business.industry, High intensity, General Medicine, Middle Aged, Ghrelin, Endocrinology, appetite, Adipose Tissue, Body Composition, Physical Endurance, Female, medicine.symptom, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, energy, fat
Abstract: The objective of this study was to evaluate the effects of high-intensity resistance and endurance exercise on body composition and plasma leptin and ghrelin concentrations in overweight individuals. One hundred participants were randomly assigned to 3 exercise interventions: high-resistance–low-aerobic exercise (Re), low-resistance–high-aerobic exercise (rE), low-resistance–low-aerobic exercise (re). Interventions began with 3 weeks of residential supervision (phase 1) after which participants had to manage the physical activity programs individually (phase 2). Body composition and plasma variables were measured at baseline and after phase 1 as well as after 3, 6, and 12 months. Significant decreases in body weight and fat were observed after phase 1 (p < 0.001) and continued at a lower rate for up to 3 months and then remained stable for the rest of the protocol. Once a body weight plateau was reached, body fat loss after the Re and rE conditions exceeded the fat loss observed in the re condition by 1.5–2 kg (p < 0.05). Leptin was significantly decreased after day 21 and month 3 (p < 0.001) and remained stable for the rest of the study. Ghrelin was significantly increased after day 21 and month 3 (p < 0.001) and returned to a level comparable to baseline between month 6 and 12 when body weight and fat had reached a plateau. In conclusion, this study reinforces the idea that an increase in exercise intensity may accentuate body fat loss before the occurrence of a body weight plateau. Resistance to further fat loss was accompanied by a decrease in plasma leptin and an increase in plasma ghrelin.
Published: 2019
Full Text: View/download PDF

18. High prevalence of psychiatric disorders in patients with skin-restricted lupus: a case-control study

Author: I, Jalenques, F, Rondepierre, C, Massoubre, E, Haffen, J P, Grand, B, Labeille, J L, Perrot, F, Aubin, F, Skowron, A, Mulliez, M, D'Incan, J, Waton, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), University Hospital of St-Etienne, Department of Dermatology, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Laboratoire de Neurosciences Intégratives et Cliniques - UFC ( NEURO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Centre Hospitalier Universitaire de Saint-Etienne ( CHU de Saint-Etienne ), Délégation à la recherche clinique et aux innovations (DRCI), CHU de Clermont-Ferrand, Institut de biologie et chimie des protéines [Lyon] ( IBCP ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO), Service de Dermatologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), and Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)
Subjects: Adult, Male, Mental Health Services, medicine.medical_specialty, Generalized anxiety disorder, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Suicide, Attempted, Dermatology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Lupus Erythematosus, Cutaneous, Prevalence, medicine, Humans, Psychiatry, ComputingMilieux_MISCELLANEOUS, Depression (differential diagnoses), Mini-international neuropsychiatric interview, Lupus erythematosus, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, Mental Disorders, [SCCO.NEUR]Cognitive science/Neuroscience, Panic disorder, Alcohol dependence, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Middle Aged, medicine.disease, 030227 psychiatry, 3. Good health, Socioeconomic Factors, Case-Control Studies, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SCCO.NEUR ] Cognitive science/Neuroscience, Major depressive disorder, Anxiety, Female, France, medicine.symptom, business
Abstract: BACKGROUND Psychiatric disorders have been extensively documented in patients with systemic lupus erythematosus (SLE). However, the prevalence of psychiatric disorders in patients with skin-restricted lupus (SRL) remains unknown, although SRL is more common than SLE. OBJECTIVES To assess current and lifetime prevalence of Axis I psychiatric disorders among outpatients with SRL and to examine the factors associated with psychiatric disorders among such patients. METHODS A multicentre case-control study involving outpatients with SRL and controls matched for sex, age and education level. The Mini International Neuropsychiatric Interview was used for psychiatric evaluation. RESULTS We evaluated 75 patients and 150 controls. Of these, 49% of patients vs. 13% of controls fulfilled the criteria for at least one current psychiatric disorder (P < 0·001). The following disorders were significantly more frequent among patients than controls: current and lifetime major depressive disorder (9% vs. 0%, P < 0·001 and 44% vs. 26%, P = 0·01), generalized anxiety disorder (23% vs. 3%, P < 0·001 and 35% vs. 19%, P = 0·03), panic disorder (7% vs. 0%, P = 0·004 and 21% vs. 3%, P < 0·001), current suicide risk (24% vs. 7%, P = 0·003), alcohol dependence (7% vs. 0%, P = 0·004) and lifetime agoraphobia (20% vs. 9%, P = 0·01). Lupus duration and lupus past treatment by thalidomide were significantly higher among patients with current psychiatric disorders. CONCLUSIONS This study demonstrates a high prevalence of several psychiatric disorders (anxiety, depression, suicide risk, alcohol dependence) in patients with SRL.
Published: 2016
Full Text: View/download PDF

19. Introducing eccentric cycling during a multidisciplinary weight loss intervention might prevent adolescents with obesity from increasing their food intake: the TEXTOO study

Author: Bruno Pereira, Maud Miguet, Kristine Beaulieu, Valérie Julian, Richard Richard, Graham Finlayson, Martine Duclos, David Thivel, EA 3533, Laboratoire des Adaptations Métaboliques à l’Exercice en conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne (UCA), CRNH Auvergne, Faculty of Medicine and Health, University of Leeds, Médecine du sport et Explorations fonctionnelles, CHU Gabriel Montpied [Clermont-Ferrand], Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Biostatistiques (DRCI), CHU Clermont-Ferrand, Médecine du sport et explorations fonctionnelles, Centre Hospitalier Universitaire Gabriel Montpied, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Unité de Nutrition Humaine (UNH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), and Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI)
Subjects: Male, medicine.medical_specialty, Adolescent, Eccentric cycling, 030309 nutrition & dietetics, media_common.quotation_subject, Appetite, 030209 endocrinology & metabolism, Experimental and Cognitive Psychology, Eating, 03 medical and health sciences, Behavioral Neuroscience, Reward system, 0302 clinical medicine, Weight loss, Intervention (counseling), medicine, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Eccentric, Obesity, Child, Exercise, media_common, 2. Zero hunger, 0303 health sciences, business.industry, Food reward, Pediatric obesity, Anthropometry, medicine.disease, Bicycling, Weight Reduction Programs, Adolescent Behavior, Physical therapy, Female, Energy intake, medicine.symptom, Cycling, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
Abstract: The present study compared the appetite responses to an inpatient eccentric vs. concentric cycling training programs in adolescents with obesity.24 adolescents with obesity (12-16yrs; Tanner 3-4) followed a 12-week multidisciplinary intervention (Phase1), after which they were randomized to concentric (CON) or eccentric (ECC) training for 12 weeks (Phase2). Assessment of anthropometrics, body composition (DXA), aerobic power (VOBody mass, BMI, and fat mass (FM%) decreased in both groups (p 0.001). FM% reduction was greater in ECC at T2 (-9.9%). EI did not change in either group at T1, but was greater at T2 relative to T1 in CON only (p 0.001,+22%). There was no correlation between the change in body mass, FM%, fat-free mass and EI. Hunger (p = 0.002) and desire to eat (p = 0.001) were higher in CON vs. ECC with no time effects nor interactions. Prospective food consumption increased in both groups with no group effect nor interaction. Satiety was not different between groups or over time. In ECC, preference for high-fat foods increased (p = 0.03), and preference (p = 0.004) and implicit wanting (p = 0.016) for sweet foods decreased.Eccentric cycling as part of an inpatient multidisciplinary weight-loss intervention might help prevent increased ad libitum energy intake compared to concentric exercise training in adolescents with obesity, potentially through distinct effects of the food reward system.
Published: 2019
Full Text: View/download PDF

20. No change in the efficacy of infectious spondylodiscitis bacteriological testing over 20 years period

Author: Martin Soubrier, Julien Lopez, Jean-Jacques Dubost, Marion Couderc, Anne Tournadre, Bruno Pereira, Unité de Nutrition Humaine (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service de rhumatologie, CHU Clermont-Ferrand, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Service de rhumatologie [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], Service de Rhumatologie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Imagerie Moléculaire et Stratégies Théranostiques - Clermont Auvergne (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Department of Clinical Research and Innovation (DRCI), CHU Clermont-Ferrand, CHU Clermont-Ferrand-Hôpital Gabriel Montpied, and Département de Rhumatologie (CLERMONT - RHUMATO)
Subjects: Male, 0301 basic medicine, Spondylodiscitis, medicine.medical_specialty, Discitis, Time Factors, Micro-organism, Biopsy, [SDV]Life Sciences [q-bio], 030106 microbiology, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Vertebral osteomyelitis, Reference Values, Humans, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Aged, Retrospective Studies, Bacteriological Techniques, business.industry, General surgery, Joint bone, Infectious spondylodiscitis, Bacterial Infections, Middle Aged, medicine.disease, 3. Good health, Blood Culture, Case-Control Studies, Reference values, Female, Microbiological test, business
Abstract: Joint Bone Spine - In Press.Proof corrected by the author Available online since dimanche 4 fevrier 2018
Published: 2018
Full Text: View/download PDF

21. Use of Patient-Specific Instrumentation (PSI) for glenoid component positioning in shoulder arthroplasty. A systematic review and meta-analysis

Author: Bruno Pereira, Roger Emery, Anne-Sophie Muller, Aurélien Mulliez, Guillaume Villatte, Peter T. A. Reilly, Service d’Orthopédie Traumatologie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Institut de Chimie de Clermont-Ferrand (ICCF), SIGMA Clermont (SIGMA Clermont)-Institut de Chimie du CNRS (INC)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), service de Biostatistiques, DRCI, CHU Clermont-Ferrand, Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Department of Bioengineering [Imperial College London], Imperial College London, and Department of Bioengineering, Imperial College London
Subjects: Patient-Specific Modeling, Medical Doctors, Glenoid Cavity, Health Care Providers, medicine.medical_treatment, [SDV]Life Sciences [q-bio], lcsh:Medicine, Glenoid cavity, Cochrane Library, Surgical planning, Diagnostic Radiology, Database and Informatics Methods, Mathematical and Statistical Techniques, 0302 clinical medicine, Medicine and Health Sciences, Medical Personnel, Database Searching, Precision Medicine, lcsh:Science, Musculoskeletal System, Instrumentation, Tomography, Orthodontics, 030222 orthopedics, Multidisciplinary, Radiology and Imaging, 3. Good health, Professions, medicine.anatomical_structure, Systematic review, Surgery, Computer-Assisted, Arthroplasty, Replacement, Shoulder, Meta-analysis, Physical Sciences, Printing, Three-Dimensional, Engineering and Technology, Anatomy, Statistics (Mathematics), Research Article, Imaging Techniques, MEDLINE, Surgical and Invasive Medical Procedures, Neuroimaging, Research and Analysis Methods, Patient Positioning, Arthroplasty, 03 medical and health sciences, Musculoskeletal System Procedures, Imaging, Three-Dimensional, Diagnostic Medicine, Physicians, medicine, Humans, Instrumentation (computer programming), Statistical Methods, Surgeons, business.industry, lcsh:R, Biology and Life Sciences, 030229 sport sciences, Computed Axial Tomography, Health Care, Shoulders, People and Places, Population Groupings, lcsh:Q, business, Mathematics, Meta-Analysis, Neuroscience
Abstract: International audience; IntroductionTotal Shoulder Arthroplasty (TSA) anatomical, reverse or both is an increasingly popular procedure but the glenoid component is still a weak element, accounting for 30–50% of mechanical complications and contributing to the revision burden. Component mal-positioning is one of the main aetiological factors in glenoid failure and thus Patient-Specific Instrumentation (PSI) has been introduced in an effort to optimise implant placement. The aim of this systematic literature review and meta-analysis is to compare the success of PSI and Standard Instrumentation (STDI) methods in reproducing pre-operative surgical planning of glenoid component positioning.Material and methodsA search (restricted to English language) was conducted in November 2017 on MEDLINE, the Cochrane Library, EMBASE and ClinicalTrials.gov. Using the search terms “Patient-Specific Instrumentation (PSI)”, “custom guide”, “shoulder”, “glenoid” and “arthroplasty”, 42 studies were identified. The main exclusion criteria were: no CT-scan analysis results; studies done on plastic bone; and use of a reusable or generic guide. Eligible studies evaluated final deviations from the planning for version, inclination, entry point and rotation. Reviewers worked independently to extract data and assess the risk of bias on the same studies.ResultsThe final analysis included 12 studies, comprising 227 participants (seven studies on 103 humans and five studies on 124 cadaveric specimens). Heterogeneity was moderate or high for all parameters. Deviations from the pre-operative planning for version (p10° of deviation or 4mm) were significantly higher with STDI than with PSI (68.6% vs 15.3% (p = 0.01)).ConclusionThis review supports the idea that PSI enhances glenoid component positioning, especially a decrease in the number of outliers. However, the findings are not definitive and further validation is required. It should be noted that no randomised clinical studies are available to confirm long-term outcomes.
Published: 2018
Full Text: View/download PDF

22. Prescription opioid analgesic use in France: Trends and impact on morbidity-mortality

Author: Denis Ardid, Chouki Chenaf, Jessica Delorme, Jean-Luc Kabore, Noémie Delage, Marie Zenut, Nicolas Authier, Bruno Pereira, Alain Eschalier, Aurélien Mulliez, Neuro-Dol - Clermont Auvergne (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Biostatistiques, Inferential, Délégation à la recherche clinique et aux innovations (DRCI), CHU de Clermont-Ferrand, Département de Pharmacologie Médicale, Agence nationale de sécurité du médicament et des produits de santé [Saint-Denis] (ANSM), VALDUC (DAM/VALDUC), Direction des Applications Militaires (DAM), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CHU Clermont-Ferrand, and Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI)
Subjects: Adult, Male, medicine.medical_specialty, Databases, Factual, [SDV]Life Sciences [q-bio], Analgesic, Population, Propoxyphene, Opium, Fentanyl, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Prevalence, Humans, 030212 general & internal medicine, Medical prescription, Mortality, education, ComputingMilieux_MISCELLANEOUS, Tramadol, Aged, Proportional Hazards Models, education.field_of_study, Dextropropoxyphene, business.industry, Codeine, Opioid overdose, Middle Aged, medicine.disease, Opioid-Related Disorders, 3. Good health, Analgesics, Opioid, Anesthesiology and Pain Medicine, Opioid, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, France, Chronic Pain, business, Oxycodone, 030217 neurology & neurosurgery, medicine.drug
Abstract: BACKGROUND While data from USA and Canada demonstrate an opioid overdose epidemic, very little nation-wide European studies have been published on this topical subject. METHODS Using a nationally representative sample of the French Claims database (>700,000 patients), the exhaustive nationwide hospital discharge database, and national mortality registry, all patients dispensed at least one prescription opioid (PO) in 2004-2017 were identified, to describe trends in PO analgesic use, shopping behaviour, opioid-related hospitalizations and deaths. Annual prevalence of PO use and shopping behaviour (≥1 day of overlapping prescriptions from ≥2 prescribers, dispensed by ≥3 pharmacies) was estimated. RESULTS In 2004-2017, the annual prevalence of weak opioid use codeine, tramadol and opium rose by 150%, 123%, and 244%, respectively (p
Published: 2018
Full Text: View/download PDF

23. The Biomarker S100B and Mild Traumatic Brain Injury: A Meta-analysis

Author: Bruno Pereira, Charlotte Oris, Vincent Sapin, Damien Bouvier, Sergio Manzano, Christoph Castellani, Julie Durif, Jeanne Simon-Pimmel, service de Biostatistiques, DRCI, CHU Clermont-Ferrand, Pediatric Emergency Division [Geneva], Geneva University Hospital (HUG), Laboratoire de Biochimie, Génétique, Reproduction et Développement (GReD ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Génétique, Reproduction et Développement (GReD), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), Délégation à la recherche clinique et aux innovations (DRCI), CHU de Clermont-Ferrand, Department of Medical Biochemistry and Molecular Biology, CHU Clermont-Ferrand, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS)
Subjects: medicine.medical_specialty, Time Factors, Traumatic brain injury, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, MEDLINE, Context (language use), S100 Calcium Binding Protein beta Subunit, 030204 cardiovascular system & hematology, Sensitivity and Specificity, 03 medical and health sciences, 0302 clinical medicine, S100 Calcium Binding Protein beta Subunit/blood, Reference Values, Internal medicine, MESH: Child, Medicine, Humans, Sampling (medicine), [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], Child, Tomography, Brain Concussion, ddc:618, MESH: Humans, MESH: Brain Concussion, business.industry, MESH: S100 Calcium Binding Protein beta Subunit, MESH: Time Factors, MESH: Reference Values, medicine.disease, Confidence interval, MESH: Sensitivity and Specificity, 3. Good health, X-Ray Computed, Data extraction, Meta-analysis, Pediatrics, Perinatology and Child Health, MESH: Biomarkers, Biomarker (medicine), Brain Concussion/blood/diagnosis/diagnostic imaging/etiology, business, Tomography, X-Ray Computed, MESH: Tomography, X-Ray Computed, 030217 neurology & neurosurgery, Biomarkers, Biomarkers/blood
Abstract: CONTEXT: The usefulness of S100B has been noted as a biomarker in the management of mild traumatic brain injury (mTBI) in adults. However, S100B efficacy as a biomarker in children has previously been relatively unclear. OBJECTIVE: A meta-analysis is conducted to assess the prognostic value of S100B in predicting intracerebral lesions in children after mTBI. DATA SOURCES: Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Scopus, and Google Scholar. STUDY SELECTION: Studies including children suffering mTBI who underwent S100B measurement and computed tomography (CT) scans were included. DATA EXTRACTION: Of 1030 articles screened, 8 studies met the inclusion criteria. RESULTS: The overall pooled sensitivity and specificity were 100% (95% confidence interval [CI]: 98%–100%) and 34% (95% CI: 30%–38%), respectively. A second analysis was based on the collection of 373 individual data points from 4 studies. Sensitivity and specificity results, obtained from reference ranges in children with a sampling time LIMITATIONS: Only patients undergoing both a CT scan and S100B testing were selected for evaluation. CONCLUSIONS: S100B serum analysis as a part of the clinical routine could significantly reduce the number of CT scans performed on children with mTBI. Sampling should take place within 3 hours of trauma. Cutoff levels should be based on pediatric reference ranges.
Published: 2018
Full Text: View/download PDF

24. How are patients with heart failure treated in primary care?

Author: Claude Dubray, Bruno Pereira, Romain Eschalier, Helene Vaillant-Roussel, Sylvaine Gibot-Boeuf, Philippe Vorilhon, Rémy Boussageon, Département de Médecine Générale, Faculté de Médecine, Université Clermont Auvergne, AutomédiCation aCcompagnement Pluriprofessionnel PatienT (ACCePPT), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), service de Biostatistiques, DRCI, CHU Clermont-Ferrand, Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Département de Médecine Générale [Clermont-Ferrand], Faculté de Médecine - Clermont-Auvergne (FM - UCA), and Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])
Subjects: Male, Drug, medicine.medical_specialty, Digoxin, media_common.quotation_subject, Primary care, Cardiologists, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, General Practitioners, Internal medicine, medicine, Humans, Pharmacology (medical), cardiovascular diseases, Thiazide, ComputingMilieux_MISCELLANEOUS, Aged, media_common, Aged, 80 and over, Heart Failure, Pharmacology, Ejection fraction, Primary Health Care, business.industry, Cardiovascular Agents, Stroke Volume, Middle Aged, medicine.disease, Drug Utilization, 3. Good health, Cross-Sectional Studies, Treatment Outcome, Drug class, Heart failure, Female, Guideline Adherence, Heart failure with preserved ejection fraction, business, medicine.drug
Abstract: OBJECTIVE The aim of this study was to assess the adherence of general practitioners (GPs) to guidelines in patients with heart failure with reduced ejection fraction (HFrEF) and to describe GPs' prescribing behavior regarding patients with heart failure with preserved ejection fraction (HFpEF). MATERIALS AND METHODS Cross-sectional study as part of the ETIC trial. Five classes of drugs were described: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs); β-blockers (BBs); mineralocorticoid receptor antagonists (MRAs); diuretics (thiazide or loop diuretics); and digoxin. RESULTS 178 patients were studied: their mean age was 73.5 years (± 10.6). Of the 128 patients with HFpEF, 81.3% received ACEIs or ARBs, 63.3% received BBs, 13.3% received MRAs, 75.8% received diuretics, and 12.5% received digoxin. Of the 50 patients with HFrEF, 84% received ACEIs or ARBs, 74% received BBs, 20% received MRAs, 76% received diuretics, and 2% received digoxin. 25% of the patients were given a drug in accordance with the recommendations for drug class but not a drug authorized for the HFrEF indication. Among the patients with HFrEF who were treated in accordance with the recommendations, target doses were achieved in 1/3 given ACEIs/ARBs, 1/4 given BBs, and 1/2 given MRAs. Only 6% of the patients had a perfect Global Adherence Indicator-3 (GAI-3) with all target doses achieved. CONCLUSION Several drugs were prescribed even though they were not recommended, and few patients were treated optimally. It seems to be necessary to develop a pragmatic tool to help GPs and cardiologists in optimizing treatment. .
Published: 2018
Full Text: View/download PDF

25. Espondilodiscitis infecciosa primaria en 51 pacientes mayores de 75 años: estudio comparativo

Author: Bruno Pereira, Benjamin Castagne, Martin Soubrier, Jean Jacques Dubost, Julien Lopez, Anne Tournadre, Marion Couderc, Département de Rhumatologie (CLERMONT - RHUMATO), CHU Clermont-Ferrand, Department of Clinical Research and Innovation (DRCI), CHU Clermont-Ferrand, Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Service de rhumatologie [Clermont-Ferrand], CHU Clermont-Ferrand-Hôpital Gabriel Montpied, Service de rhumatologie, Imagerie Moléculaire et Stratégies Théranostiques - Clermont Auvergne (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Service de Rhumatologie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Unité de Nutrition Humaine (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], Imagerie Moléculaire et Stratégies Théranostiques (IMoST), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])
Subjects: Spondylodiscitis, medicine.medical_specialty, health care facilities, manpower, and services, [SDV]Life Sciences [q-bio], education, [SDV.CAN]Life Sciences [q-bio]/Cancer, Patient characteristic, 03 medical and health sciences, 0302 clinical medicine, Vertebral osteomyelitis, Osteomielitis vertebral, medicine, Mayores, 030212 general & internal medicine, health care economics and organizations, Gynecology, business.industry, Infectious spondylodiscitis, General Medicine, social sciences, medicine.disease, humanities, 3. Good health, Característica del paciente, Older people, business, 030217 neurology & neurosurgery, Espondilodiscitis infecciosa
Abstract: Resumen Antecedentes y objetivo Se ha demostrado que la incidencia de la espondilodiscitis infecciosa se incrementa con la edad; sin embargo, esto no ha sido investigado ampliamente en los mayores. Material y metodos Estudio retrospectivo, en un unico centro, que incluyo a los pacientes hospitalizados en nuestro Departamento de Reumatologia debido a espondilodiscitis infecciosa entre 2000 y 2015, y comparacion de los pacientes mayores de 75 con los pacientes mas jovenes. Resultados De los 152 pacientes, 51 (33,6%) eran ≥ 75 anos, 59 de entre 61 y 74, y 42 ≤ 60. Los pacientes ≥ 75 estaban frecuentemente institucionalizados (7,8 frente a 0; p = 0,02), estuvieron menos sujetos a los factores de riesgo de infeccion (27,5 frente a 54,5%; p = 0,02), pero no difirieron del resto en cuanto a la frecuencia de diabetes y cancer. El tiempo de diagnostico fue menor para los pacientes menores de 60 anos (23 frente a 30 frente a 30 dias para cada grupo de edad, respectivamente; p Conclusion La edad es un factor de riesgo para la espondilodiscitis primaria, que se asocia a una mortalidad significativa en los pacientes mayores de 75 anos (10%). Para estos pacientes mayores, la espondilodiscitis no comporta otras caracteristicas distintivas.
Published: 2018
Full Text: View/download PDF

26. Peanut gastrointestinal delivery oral immunotherapy in adolescents: Results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study)

Author: Etienne Merlin, Emmanuelle Rochette, Bruno Pereira, Paul-Olivier Rouzaire, J.-L. Fauquert, L. Bernard, Elodie Michaud, Nelly Gourdon-Dubois, Bertrand Evrard, Pôle pédiatrique, Unité d’allergologie de l’enfant, Centre Hospitalier Universitaire Estaing, CIC Clermont Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Pharmacologie Clinique-CHU Gabriel-Montpied, CHU Clermont-Ferrand, CIC - Clermont Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM), Pole pédiatrique, Unité d’allergologie de l’enfant, Unité de Biostatistiques, Direction de la Recherche Clinique et Innovation (DRCI), Centre Hospitalier Universitaire de Clermont-Ferrand, Département de Pharmacie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut de Chimie de Clermont-Ferrand - Clermont Auvergne (ICCF), Sigma CLERMONT (Sigma CLERMONT)-Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), Service d’Immunologie, Centre Hospitalier Universitaire Gabriel Montpied, UFR Pharmacie, ERTICa, Université d'Auvergne (Clermont Ferrand 1) (UdA), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Agence Nationale de la Recherche RBHP2013 Fauquert, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-Centre de Pharmacologie Clinique, Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Institut de Chimie de Clermont-Ferrand (ICCF), SIGMA Clermont (SIGMA Clermont)-Institut de Chimie du CNRS (INC)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), CHU Gabriel Montpied [Clermont-Ferrand], Université d'Auvergne - Clermont-Ferrand I (UdA), Unité de Nutrition Humaine (UNH), and Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])
Subjects: Male, 0301 basic medicine, Arachis, capsules, Peanut allergy, Placebo-controlled study, Administration, Oral, Gastroenterology, 0302 clinical medicine, Prevalence, Immunology and Allergy, Medicine, Ingestion, Child, allergie alimentaire, ComputingMilieux_MISCELLANEOUS, Oral food challenge, Age Factors, peanut allergy, oral immunotherapy, Dysphagia, 3. Good health, Treatment Outcome, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, medicine.symptom, gastrointestinal delivery, medicine.medical_specialty, Randomization, Immunology, Placebo, 03 medical and health sciences, Internal medicine, anaphylaxis, Humans, Peanut Hypersensitivity, Adverse effect, business.industry, Allergens, Antigens, Plant, Immunoglobulin E, medicine.disease, food sensitivity, Gastrointestinal Tract, 030104 developmental biology, 030228 respiratory system, Desensitization, Immunologic, Immunoglobulin G, adolescent, peanut, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Biomarkers, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, cacahuete
Abstract: Background Oral immunotherapy to peanut is effective in desensitizing patients but has significant side effects including anaphylaxis and gastrointestinal symptoms. In most protocols, peanut is administered in a vehicle food. Objective In an exclusively adolescent population, we tested a new approach using sealed capsules of peanut (gastrointestinal delivery oral immunotherapy or GIDOIT) to bypass the upper gastrointestinal tract. The primary aim was to assess the efficacy of the oral build‐up phase of GIDOIT and the secondary aim to analyse its safety. Methods Adolescents with a history of a clinical allergic reaction after peanut ingestion were included in a 2‐armed, parallel‐design, individually randomized, double‐blind, placebo‐controlled, multicentre trial after a positive double‐blind placebo‐controlled oral food challenge (DBPCFC1). A central randomization centre used computer‐generated tables to allocate treatments. Peanut (or placebo) capsules were ingested daily over a period of 24 weeks with increments every 2 weeks from 2 to 400 mg of peanut protein (pp). Primary outcome was tolerance of 400 mg of pp at DBPCFC2. Results Thirty patients were included between September 2013 and May 2014. At DBPCFC2, unresponsiveness to 400 mg of pp was achieved in 17/21 peanut group patients (2 withdrawn patients) and 1/9 in the placebo group (Intention‐to‐treat analysis, P < .001, absolute difference = 0.7, 95%IC 0.43 0.96). Oropharyngeal symptoms were equally frequent in both groups. No dysphagia or other signs of eosinophilic oesophagitis occurred. Digestive adverse events (AE) were more frequent in the treated group (P = .02), but mild and without compliance issues. Only one severe advent event led to withdrawal in a patient who ingested twice the investigated treatment. Peanut‐specific humoral immune responses were modulated. Conclusion The GIDOIT protocol demonstrated clinical and immunological efficacy and had an acceptable level of safety with weak oropharyngeal symptoms, no dysphagia, mild digestive events and few severe systemic AE.
Published: 2018
Full Text: View/download PDF

27. The Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from the International ASAS-COMOSPA Study

Author: Maxime Dougados, Anna Molto, Marion Couderc, Aurélien Tiple, Martin Soubrier, Bruno Pereira, Imagerie Moléculaire et Stratégies Théranostiques - Clermont Auvergne (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Université Paris Descartes - Paris 5 (UPD5), CHU Cochin [AP-HP], Université Sorbonne Paris Cité (USPC), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Department of Clinical Research and Innovation (DRCI), CHU Clermont-Ferrand, Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], CHU Clermont-Ferrand, Service de rhumatologie [Clermont-Ferrand], CHU Clermont-Ferrand-Hôpital Gabriel Montpied, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)
Subjects: Adult, Male, medicine.medical_specialty, Disease duration, [SDV]Life Sciences [q-bio], Immunology, Renal function, [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease, Comorbidity, Kidney, Kidney Function Tests, Severity of Illness Index, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Rheumatology, Disease severity, Internal medicine, Spondylarthritis, medicine, Prevalence, Immunology and Allergy, Humans, In patient, 030212 general & internal medicine, BASDAI, ComputingMilieux_MISCELLANEOUS, 030203 arthritis & rheumatology, Ankylosing spondylitis, Nonsteroidal, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Age Factors, Middle Aged, medicine.disease, 3. Good health, chemistry, Female, Kidney Diseases, business, Glomerular Filtration Rate
Abstract: Objective.To assess the prevalence and association of renal dysfunction in patients with spondyloarthritis (SpA).Methods.The ASAS-COMOSPA (Assessment of Spondyloarthritis international Society-COMOrbidities in SPondyloArthritis) was an international study (22 participating countries from 4 continents) investigating comorbidities in SpA. Renal function was assessed based on estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation. SpA characteristics and risk factors for renal impairment were collected. Nonsteroidal antiinflammatory drug (NSAID) use was assessed based on current intake (last 3 mos).Results.Of the 3984 patients recruited, 2098 (52.6%) were analyzed after excluding outliers and patients with no available eGFR measurement [male sex: 63.5%; age: 45.3 yrs; disease duration: 8.6 years; HLA-B27+: 73.1%; Bath Ankylosing Spondylitis Activity Index (BASDAI): 3.6/10]. Overall, 153 patients (5.2%, mean age: 53.6 yrs) exhibited an eGFR < 60 ml/min/1.73 m2. In univariate analysis, renal impairment was associated with age (p < 0.001), HLA-B27 positivity (p = 0.003), several cardiovascular (CV) risk factors (history of hypertension, p < 0.001; systolic blood pressure, p = 0.009; diabetes, p = 0.005; and Framingham risk score, p < 0.001), disease activity scores [BASDAI, p = 0.001; Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP), p < 0.001], functional variables (Bath Ankylosing Spondylitis Functional Index, p < 0.001), inflammatory biomarkers (erythrocyte and CRP, both p < 0.001), and NSAID intake since onset of disease (percentage of days, p = 0.008). However, there was no association with disease duration, disease severity, or ASAS-NSAID score. In multivariate analysis, age (45–59 yrs: OR 1.9, > 60 yrs: OR 6.2), HLA-B27 positivity (OR 0.51), and CRP (OR 1.3) remained significantly associated with eGFR < 60 ml/min/1.73 m2.Conclusion.Renal impairment was associated with age, HLA-B27 positivity, and inflammation, though not with CV risk factors, disease severity, or NSAID intake in patients with SpA.
Published: 2017
Full Text: View/download PDF

28. Substantial variability across individuals in the vascular and nutrigenomic response to an acute intake of curcumin: A randomizsed controlled trial

Author: Jean René Lusson, Bruno Pereira, Damien Richard, Andrzej Mazur, Claude Dubray, Céline Lambert, Nicolas Barber-Chamoux, Christine Morand, Véronique Habauzit, Marie-Anne Verny, Dragan Milenkovic, Céline Boby, Unité de Nutrition Humaine (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Délégation à la Recherche Clinique et à l'Innovation (DRCI), CHU Clermont-Ferrand, Unité Mixte de Recherche sur les Herbivores - UMR 1213 (UMRH), Institut National de la Recherche Agronomique (INRA)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Centre d’Investigation Clinique (CIC), Institut National de la Santé et de la Recherche Médicale (INSERM), Université d'Auvergne - Clermont-Ferrand I (UdA), Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université, Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), service de Biostatistiques, DRCI, Centre Hospitalier Universitaire de Clermont-Ferrand, Unité Biostatistique, Institut de Recherche en Gestion et en Economie (IREGE), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Unité Mixte de Recherches sur les Herbivores - UMR 1213 (UMRH), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Recherche Agronomique (INRA), Institut Pascal - Clermont Auvergne (IP), Sigma CLERMONT (Sigma CLERMONT)-Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), Université d'Auvergne (Clermont Ferrand 1) (UdA), CIC 501, Université Clermont Auvergne (UCA), Biostatistics Unit (DRCI), Clinical pharmacology, Cardiologie, Hôpital Privé Jacques Cartier [Massy], UMR 766, Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Institut National de la Recherche Agronomique (INRA)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS), Unité de Nutrition Humaine - Clermont Auvergne ( UNH ), Université Clermont Auvergne ( UCA ) -Institut national de la recherche agronomique [Auvergne/Rhône-Alpes] ( INRA Auvergne/Rhône-Alpes ), Délégation à la Recherche Clinique et à l'Innovation ( DRCI ), Unité Mixte de Recherches sur les Herbivores ( UMR 1213 Herbivores ), VetAgro Sup ( VAS ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Recherche Agronomique ( INRA ), Centre d’Investigation Clinique ( CIC ), Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université d'Auvergne (Clermont Ferrand 1) ( UdA ), Institut Pascal (IP), SIGMA Clermont (SIGMA Clermont)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), ARCA (Association de Recherche en Cardiologie d'Auvergne), Unité de Nutrition Humaine ( UNH ), Institut National de la Recherche Agronomique ( INRA ) -Université d'Auvergne - Clermont-Ferrand I ( UdA ) -Clermont Université, Institut de Recherche en Gestion et en Economie ( IREGE ), Université Savoie Mont Blanc ( USMB [Université de Savoie] [Université de Chambéry] ), Institut Pascal - Clermont Auvergne ( IP ), Sigma CLERMONT ( Sigma CLERMONT ) -Université Clermont Auvergne ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), Institut National de la Santé et de la Recherche Médicale, Centre de Recherche en Nutrition Humaine (CRNH). FRA., ProdInra, Archive Ouverte, VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut National de la Recherche Agronomique (INRA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, and SIGMA Clermont (SIGMA Clermont)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, 0301 basic medicine, Pathology, Physiology, fonction endothéliale, [ SDV.AEN ] Life Sciences [q-bio]/Food and Nutrition, 030232 urology & nephrology, Individuality, vascular system, 030204 cardiovascular system & hematology, nutrigenomic, law.invention, essai clinique, chemistry.chemical_compound, Nutrigenomics, 0302 clinical medicine, Randomized controlled trial, endothelial function, law, curcumin, nutrigénomique, ComputingMilieux_MISCELLANEOUS, Cross-Over Studies, [ INFO.INFO-IM ] Computer Science [cs]/Medical Imaging, blood pressure, food and beverages, clinical trial, Middle Aged, 3. Good health, Vasodilation, Population study, Female, Cardiology and Cardiovascular Medicine, mode d'apport, Biotechnology, medicine.medical_specialty, Subgroup analysis, Placebo, nutragenomics, random selection, inter-individual variability, 03 medical and health sciences, Double-Blind Method, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, Internal Medicine, medicine, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Humans, randomisation, 030109 nutrition & dietetics, business.industry, système vasculaire, Crossover study, Clinical trial, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, curcumine, Blood pressure, chemistry, Curcumin, Endothelium, Vascular, Transcriptome, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Food Science
Abstract: cope Curcumin exerts biological activities of interest in cardiovascular prevention. However, its vascular protective effect is still poorly investigated in humans. The present study aims to assess vasculat effect of an acute intake of curcumin and its nutrigenomic impact in circulating immune cells. Methods and results In a randomised, double-blind, crossover design, eighteen healthy smokers consumed a placebo or a 5-gram of curcumin. Before and two hours after the intake, vascular function measurements were performed by using flow-mediated dilation (FMD). In addition, endothelial function in the microcirculation and blood pressure were evaluated. Plasma curcumin concentrations and changes in gene expression in peripheral blood mononuclear cells (PBMC) were analysed. No significant effect of curcumin on FMD was observed when considering the entire study population, mainly due to a high inter-individual variability. A subgroup analysis according to the gender or the cardiovascular-risk score revealed a significant effect of curcumin on FMD in women and in subjects presenting lower cardiovascular risk. No change in gene expression was observed when data were analysed for all volunteers but changes in expression were observed when analyzed according to gender. Conclusions This clinical trial highlights that a substantial variability in efficacy of curcumin exists across individuals. This article is protected by copyright. All rights reserved
Published: 2017
Full Text: View/download PDF

29. Epidural analgesia in critically ill patients with acute pancreatitis: the multicentre randomised controlled EPIPAN study protocol

Author: Etienne Escudier, Laurence Roszyk, Achille Sossou, Vincent Sapin, Philippe Guerci, Elodie Caumon, Matthieu Jabaudon, Pierre-François Laterre, Bruno Pereira, Stéphanie Bulyez, Etienne Imhoff, C.-P. Heidegger, Jean-Michel Constantin, Samir Jaber, Lise Bernard, Pierre-Eric Danin, Pierre-Marie Bertrand, Dominique Morand, Russell Chabanne, Jean-Yves Lefrant, Leo Buhler, CHU Clermont-Ferrand, Department of Clinical Research and Innovation (DRCI), CHU Clermont-Ferrand, Department of Perioperative Medicine, CHU Clermont-Ferrand, Department of Medical Biochemistry and Molecular Biology, CHU Clermont-Ferrand, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires (EA 2992), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Intensive Care Unit, Cannes general hospital, Cannes, Intensive Care Unit, St Luc University Hospital, Faculté de Médecine [Nancy], Université de Lorraine (UL), Inserm U1065, Centre Méditerranéen de Médecine Moléculaire, Intensive Care Unit, Annecy Genevois general hospital, Annecy, Department of Anesthesiology and Critical Care Medicine, Emile-Roux general hospital, Le Puy-en-Velay, Laboratoire de Biochimie, Centre Hospitalier Universitaire de Clermont-Ferrand, Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Service d'Anésthésie Réanimation [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de Biochimie et Génétique Moléculaire [CHU Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Subjects: Epidural analgesia, medicine.medical_treatment, Lung injury, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, 030202 anesthesiology, law, Protocol, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Medicine, Intensive care unit, Epidural administration, ComputingMilieux_MISCELLANEOUS, Mechanical ventilation, Randomised controlled trial, ddc:617, business.industry, Intensive Care, General Medicine, medicine.disease, 3. Good health, Acute pancreatitis, Respiratory failure, Anesthesia, Pancreatitis, 030211 gastroenterology & hepatology, business
Abstract: Background Acute pancreatitis (AP) is associated with high morbidity and mortality in its most severe forms. Most patients with severe AP require intubation and invasive mechanical ventilation, frequently for more than 7 days, which is associated with the worst outcome. Recent increasing evidence from preclinical and clinical studies support the beneficial effects of epidural analgesia (EA) in AP, such as increased gut barrier function and splanchnic, pancreatic and renal perfusion, decreased liver damage and inflammatory response, and reduced mortality. Because recent studies suggest that EA might be a safe procedure in the critically ill, we sought to determine whether EA reduced AP-associated respiratory failure and other major clinical outcomes in patients with AP. Methods and analysis The Epidural Analgesia for Pancreatitis (EPIPAN) trial is an investigator-initiated, prospective, multicentre, randomised controlled two-arm trial with assessor-blinded outcome assessment. The EPIPAN trial will randomise 148 patients with AP requiring admission to an intensive care unit (ICU) to receive EA (with patient-controlled epidural administration of ropivacaine and sufentanil) combined with standard care based on current recommendations on the treatment of AP (interventional group), or standard care alone (reference group). The primary outcome is the number of ventilator-free days at day 30. Secondary outcomes include main complications of AP (eg, organ failure and mortality, among others), levels of biological markers of systemic inflammation, epithelial lung injury, renal failure, and healthcare-associated costs. Ethics and dissemination The study was approved by the appropriate ethics committee ( CPP Sud-Est VI ). Informed consent is required. If the combined application of EA and standard care proves superior to standard care alone in patients with AP in the ICU, the use of EA may become standard practice in experienced centres, thereby decreasing potential complications related to AP and its burden in critically ill patients. The results will be disseminated in a peer-reviewed journal. Trial registration number NCT02126332.
Published: 2017
Full Text: View/download PDF

30. RT-qPCR for PHOX2B mRNA is a highly specific and sensitive method to assess neuroblastoma minimal residual disease in testicular tissue

Author: Nathalie Rives, Nadège Rouel, Pascale Halle, Victoria Grèze, Florence Brugnon, Andrei Tchirkov, Justyna Kanold, F. Chambon, Bruno Pereira, Anne Sophie Gremeau, Service d'hématologie pédiatrique, CHU Clermont-Ferrand-CIC Inserm 501, Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Laboratoire BDR CECOS - FIV AMP, CHU Estaing [Clermont-Ferrand], Gamétogenèse et Qualité du Gamète - ULR 4308 (GQG), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Lille, CHU Rouen, Normandie Université (NU), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Génétique, Reproduction et Développement (GReD), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS)
Subjects: Cancer Research, Pathology, medicine.medical_specialty, fertility preservation, [SDV]Life Sciences [q-bio], testicular tissue, Biology, Andrology, 03 medical and health sciences, neuroblastoma, 0302 clinical medicine, Neuroblastoma, medicine, Azoospermia, 030219 obstetrics & reproductive medicine, Oncogene, Snap freezing, [SDV.BDLR]Life Sciences [q-bio]/Reproductive Biology, Cell cycle, medicine.disease, Minimal residual disease, Molecular medicine, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, reverse transcription quantitative polymerase chain reaction, minimal residual disease, Bone marrow
Abstract: International audience; Neuroblastoma (NB) is the most common type of extracranial solid tumor in children with a high prevalence in toddlers. For childhood cancer survivors, preservation of reproductive potential is an important factor for quality of life. The optimization of NB minimal residual disease (MRD) detection in testicular tissue is crucial to evaluate the risk of malignant cell reintroduction. The first step in the present study was to assess the accuracy of reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to detect tyrosine hydroxylase (TH), paired-like homeobox 2b (PHOX2B) and doublecortin (DCX) mRNA expression in frozen/thawed testicular tissues of patients with non-obstructive azoospermia (NOA) contaminated (in vitro model) with an increasing number of IMR-32 and SK-N-SH NB cells. Testicular tissues were frozen by slow or snap freezing. The second step was to determine the expression levels of these markers in testicular samples from 4 pre-pubertal males (2 with stage IV NB and 2 with non-NB malignancy). The yield of extracted RNA was similar in testicular samples frozen by slow or snap freezing. In the in vitro model, TH and DCX transcripts were detected in uncontaminated testicular tissues, whereas PHOX2B mRNA was not detected. There was a strong positive association between the number of NB cells used for contamination and PHOX2B transcript levels. For IMR-32 and SK-N-SH NB cell lines, specificity and sensitivity rates of detection were 100% for PHOX2B following in vitro contamination with 10 tumor cells. In testicular samples from pre-pubertal males with and without NB, PHOX2B mRNA expression was not observed, but high expression levels of TH and DCX mRNA were detected, which were similar to expression detected in the in vitro model. Among the markers used in blood and bone marrow for NB MRD studies, the detection of PHOX2B transcripts by RT-qPCR may provide an accurate assessment of NB cells in testicular tissues from males who require fertility preservation.
Published: 2017
Full Text: View/download PDF

31. Satiety responsiveness but not food reward is modified in response to an acute bout of low versus high intensity exercise in healthy adults

Author: Maud Miguet, Yves Boirie, Marie-Eve Mathieu, P. M. Genin, Marwa Khammassi, Graham Finlayson, André J. Tremblay, John E. Blundell, Alicia Fillon, Martine Duclos, Lore Metz, B. Pereira, Vicky Drapeau, David Thivel, EA 3533, Laboratoire des Adaptations Métaboliques à l’Exercice en conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne (UCA), Appetite Control and Energy Balance Research Group, University of Leeds, Centre de SSR Nutrition-Obésité UGECAM, DRCI, Biostatistiques, CHU Clermont-Ferrand, Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Nutrition clinique, Centre Hospitalier Universitaire Gabriel Montpied, CRNH Auvergne, Médecine du sport et exploration fonctionnelle, CHU Gabriel Montpied [Clermont-Ferrand], Institute of Nutrition and Functional Foods INAF, Université Laval, School of kinesiology and Physical Activity Sciences, Université de Montréal (UdeM), Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Unité de Nutrition Humaine (UNH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and National French University Institute (IUF)
Subjects: Male, 0301 basic medicine, medicine.medical_specialty, Intensity, media_common.quotation_subject, Appetite, 030209 endocrinology & metabolism, Satiation, Affect (psychology), Food Preferences, Young Adult, 03 medical and health sciences, Oxygen Consumption, 0302 clinical medicine, Reward, Satiety quotient, Surveys and Questionnaires, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Medicine, Young adult, Exercise, General Psychology, Aerobic capacity, media_common, 2. Zero hunger, Meal, 030109 nutrition & dietetics, Nutrition and Dietetics, business.industry, digestive, oral, and skin physiology, Food reward, VO2 max, Anthropometry, Food, Body Composition, Physical therapy, Female, Energy Intake, business, human activities, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Body mass index
Abstract: To compare the effect of iso-caloric low and high intensity exercises on Satiety Quotient and Food Reward in response to a fixed meal in healthy young adults. Anthropometric measurements, body composition (BIA), aerobic capacity (VO2 max) and food preferences were assessed in 19 healthy normal-weight young adults (21 +/- 0.5 years old, 10 men). They randomly completed 3 experimental sessions: i) control session without exercise (CON); ii) High Intensity exercise session (HIE); iii) Low intensity exercise session (LIE). Thirty minutes after exercise or rest, then received a fixed lunch. Food reward (Leeds Food Preference Questionnaire) was assessed before and after the meal. Appetite sensations were assessed at regular intervals, SQ was calculated from the lunch meal and self-reported food intake was collected for the rest of the day. Mean body weight was 66.7 +/- 9.2 kg, body mass index was 22.3 +/- 2.9 kg/m2 and FM% was 18.7 +/- 6.8%. Appetite feelings did not differ between conditions and were not affected by exercise. SQ for satiety was not different between conditions. SQ hunger on CON was significantly higher than on LIE and HIE (p= 0.05) with no difference between exercise conditions. SQ for desire to eat was significantly higher on CON versus HIE (p= 0.01) with no differences between CON and LIE and between exercise sessions. SQ PFC was significantly lower on HIE compared with CON (p= 0.02) with no differences between LIE and CON and between LIE and HIE. Food reward was not significantly different between the three condition as well as self-reported total food and macronutrient intake for the rest of the days. Acute exercise, depending on its intensity, might affect the satiating response to food intake in healthy adults, without altering food reward.
Published: 2020
Full Text: View/download PDF

32. A new equation based on the 6-min walking test to predict VO2peak in women with obesity

Author: Valérie Julian, Lore Metz, David Thivel, Bruno Peirrera, Ruddy Richard, Martine Duclos, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Unité de Nutrition Humaine (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Department of Sport Medicine and Functional Exploration, CHU Gabriel Montpied [Clermont-Ferrand], Service Médecine du Sport et Explorations Fonctionnelles [CHU Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques - Clermont Auvergne (AME2P), Faculté des Sciences du SportFaculté des Sciences du Sport, UFR STAPS-Université Clermont Auvergne (UCA), Biostatistics Unit (DRCI), Université Clermont Auvergne (UCA), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), and Centre Hospitalier Universitaire Gabriel Montpied
Subjects: medicine.medical_specialty, obesity, medicine.medical_treatment, [SDV]Life Sciences [q-bio], 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Waist–hip ratio, Physical medicine and rehabilitation, medicine, Aerobic exercise, 030212 general & internal medicine, capacité aérobie, 6-min walking test, Aerobic capacity, 2. Zero hunger, Rehabilitation, exercise, business.industry, indice de masse corporelle, medicine.disease, Obesity, aerobic capacity, obésité, exercice, Walk test, Physical therapy, business, Body mass index, human activities, 6 min walking test
Abstract: In press; The 6-min walking test (6 MWT) is commonly used to assess obese patients' aerobic fitness, but it has rarely been compared with a direct measurement of maximal aerobic capacities (VO2max or VO2peak) in obese adults. The aim of this study was to investigate the relationship between the distance covered during a 6 MWT with objectively measured VO2peak and to propose a new equation to predict VO2peak from this walking test in obese patients.One hundred and thirty-seven obese patients (45.6 ± 12.5 years) admitted to our hospital for a multidisciplinary rehabilitation program were enrolled. After assessment of their body composition, the participants were asked to perform a 6 MWT and their maximal aerobic capacities (VO2peak) were measured..There is a significant linear relation between VO2peak and the distance covered during the 6 MWT (p
Published: 2017
Full Text: View/download PDF

33. WittyFit-Live Your Work Differently: Study Protocol for a Workplace-Delivered Health Promotion

Author: Martine Duclos, Pascal Huguet, Samuel Dewavrin, Bruno Pereira, Frédéric Dutheil, Thomas Cornet, Jean-Claude Chatard, Geraldine Naughton, Service Santé Travail Environnement, Centre Hospitalier Universitaire de Clermont-Ferrand, Laboratoire de Psychologie Sociale et Cognitive - Clermont Auvergne (LAPSCO), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS), Université Clermont Auvergne (UCA), Australian Catholic University, Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Service de Médecine du Sport, CHU Toulouse [Toulouse]-Hôpital Larrey, WittyFit, Physiologie de l'Exercice, Centre Hospitalier Universitaire de Saint-Etienne, Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM ), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Université de Lyon, Université Jean Monnet (Saint-Etienne), Délégation à la Recherche Clinique et à l'Innovation (DRCI), Stress physiologique et psychosocial, Bien-Être [CHU Clermont-Ferrand Gabriel-Montpied] (Service Santé Travail Environnement), CHU Gabriel Montpied [Clermont-Ferrand]-Centre de Pathologie Professionnelle [CHU Clermont-Ferrand Gabriel-Montpied], Pontificia Universidad Católica Argentina (UCA), Service d'exploration de la fonction respiratoire et de médecine du sport, CHU Toulouse [Toulouse], Australian National University (ANU), Laboratoire de psychologie cognitive (LPC), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Université Jean Monnet [Saint-Étienne] (UJM), Unité de Biostatistiques [CHU Clermont-Ferrand] (Délégation à la Recherche Clinique et à l'Innovation - DRCI), CHU Clermont-Ferrand, Laboratoire de Psychologie Sociale et Cognitive (LAPSCO), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Australian Catholic University (ACU), Unité de Nutrition Humaine (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM), Université Clermont Auvergne (UCA)-Institut National de la Recherche Agronomique (INRA), Dutheil, Frédéric, Médecine du Sport [CHU Toulouse], Département Chirurgie Orthopédique et traumatologique [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])
Subjects: 020205 medical informatics, espérance de vie, Applied psychology, physical activity, morbidity, 02 engineering and technology, travailleur, absenteeism, stress, 0302 clinical medicine, well-being, Protocol, 0202 electrical engineering, electronic engineering, information engineering, morbidité, 030212 general & internal medicine, anxiety, behavior, depression, health, lifestyle, management, mhealth, mobile app, mortality, musculoskeletal disorders, nutrition, organization, public health, sleep, work, mHealth, ComputingMilieux_MISCELLANEOUS, education.field_of_study, Behavior change, General Medicine, Santé publique et épidémiologie, 8. Economic growth, [SCCO.PSYC]Cognitive science/Psychology, Absenteeism, Psychology, étude de cohorte, medicine.medical_specialty, Population, 03 medical and health sciences, Nursing, medicine, education, objet connecté, bien-être, Public health, Middle management, statistical study, Health promotion, santé publique, Life expectancy, life expectancy, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, étude statistique
Abstract: We express our sincere gratitude to Marie-Anne Cousseau who established the public-private partnership between WittyFit and the University Hospital of Clermont-Ferrand,France.This study is integrally funded by WittyFit,Asniere-sur-Seine; International audience; BACKGROUND: Morbidity before retirement has a huge cost, burdening both public health and workplace finances. Multiple factors increase morbidity such as stress at work, sedentary behavior or low physical activity, and poor nutrition practices. Nowadays, the digital world offers infinite opportunities to interact with workers. The WittyFit software was designed to understand holistic issues of workers by promoting individualized behavior changes at the workplace.OBJECTIVE: The shorter term feasibility objective is to demonstrate that effective use of WittyFit will increase well-being and improve health-related behaviors. The mid-term objective is to demonstrate that WittyFit improves economic data of the companies such as productivity and benefits. The ultimate objective is to increase life expectancy of workers.METHODS: This is an exploratory interventional cohort study in an ecological situation. Three groups of participants will be purposefully sampled: employees, middle managers, and executive managers. Four levels of engagement are planned for employees: commencing with baseline health profiling from validated questionnaires; individualized feedback based on evidence-based medicine; support for behavioral change; and formal evaluation of changes in knowledge, practices, and health outcomes over time. Middle managers will also receive anonymous feedback on problems encountered by employees, and executive top managers will have indicators by division, location, department, age, seniority, gender and occupational position. Managers will be able to introduce specific initiatives in the workplace. WittyFit is based on two databases: behavioral data (WittyFit) and medical data (WittyFit Research). Statistical analyses will incorporate morbidity and well-being data. When a worker leaves a workplace, the company documents one of three major explanations: retirement, relocation to another company, or premature death. Therefore, WittyFit will have the ability to include mortality as an outcome. WittyFit will evolve with the waves of connected objects further increasing its data accuracy. Ethical approval was obtained from the ethics committee of the University Hospital of Clermont-Ferrand, France. RESULTS: WittyFit recruitment and enrollment started in January 2016. First publications are expected to be available at the beginning of 2017. CONCLUSIONS: The name WittyFit came from Witty and Fitness. The concept of WittyFit reflects the concept of health from the World Health Organization: being spiritually and physically healthy. WittyFit is a health-monitoring, health-promoting tool that may improve the health of workers and health of companies. WittyFit will evolve with the waves of connected objects further increasing its data accuracy with objective measures. WittyFit may constitute a powerful epidemiological database. Finally, the WittyFit concept may extend healthy living into the general population
Published: 2017
Full Text: View/download PDF

34. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study

Author: Nguyen, Minh Vu Chuong, Romand, Xavier, Trocme, Candice, Courtier, Anaïs, Marotte, Hubert, Thomas, Thierry, Miossec, Pierre, Tebib, Jacques, Grange, Laurent, Toussaint, Bertrand, Gaudin, Philippe, Nourisson, Cynthia, Soubrier, Martin, Mulliez, Aurelien, Baillet, Athan, Bardin, Thomas, Combe, Bernard, Dougados, Maxime, Flipo, René-Marc, Ravaud, Philippe, Tournadre, Anne, Derambure, C., Dzangue-Tchoupou, G., Bérard, C., Vergne, N., Hiron, M., D’Agostino, M., Musette, P., Lequerré, Thierry, Ruyssen-Witrand, Adeline, Degboé, Yannick, Cantagrel, Alain, Nigon, D., Lukas, C., Scaramuzzino, S, Allanore, Y., Schaeverbeke, Thierry, Morel, J., Sibilia, Jean, Cambon-Thomsen, A., Dieudé, P., Constantin, A, Nocturne, G., Virone, A., Ng, Wan-Fai, Le Guern, V., Hachulla, E., Cornec, D., Daien, C., Bienvenu, B., Marcelli, C., Wendling, D., Amoura, Z., Dhote, R., Lavigne, C., Fior, R., Gottenberg, Jacques-Eric, Seror, R., Mariette, Xavier, Eble, V., Legallicier, B., Joly, P., Caron, F., Tamion, F., Ducrotté, P., Lévesque, H., Ménard, J.-F., Jouen, F., Guerrot, D., Marié, I., D'Agostino, Maria-Antonietta, Wakefield, Richard, Berner-Hammer, Hilde, Vittecoq, Olivier, Filippou, Georgios, Bálint, Péter, Möller, Ingrid, Iagnocco, Annamaria, Naredo, Esperanza, Ostergaard, Mikkel, Boers, Maarten, Gaillez, Corine, Van Holder, Karina, Le Bars, Manuela, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Thérapeutique Recombinante Expérimentale (TIMC-IMAG-TheREx), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Groupe de Recherche et d'Etude du Processus Inflammatoire (GREPI), Centre National de la Recherche Scientifique (CNRS)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Service de Rhumatologie [Saint-Etienne], Hôpital de Bellevue-CHU Saint-Etienne, Service d'Endocrinologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Department of Immunogenomics, Mixed Unit HCL-BioMerieux, Hopital E. Herriot, Hospices Civils de Lyon (HCL), Service de Rhumatologie, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Service de rhumatologie, CHU Clermont-Ferrand, Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Lapeyronie [Montpellier] (CHU), Service de rhumatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Unité de Nutrition Humaine (UNH), Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université-Institut National de la Recherche Agronomique (INRA), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Laboratoire de Mathématiques Raphaël Salem (LMRS), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), CHU Toulouse [Toulouse], Service de rhumatologie et réadaptation fonctionelle, CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Hôpital Purpan [Toulouse], Centre de rhumatologie, CHU Purpan, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Bordeaux [Bordeaux], Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Institute of Cellular Medicine [Newcastle], Newcastle University [Newcastle], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Rhumatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital Avicenne [AP-HP], Hôpital Antoine Béclère, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immuno-Rhumatologie Moléculaire, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA), CHU Le Kremlin-Bicêtre (Rheumatology Department), Department of Rheumatology, Service de Médecine Interne [CHU Rouen], Service de Néphrologie [Rouen], Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM ), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Unité de biostatistiques [CHU Rouen], Physiopathologie et biothérapies des maladies inflammatoires et autoimmunes, Service de Dermatologie [Rouen], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Academic Unit of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, Chapel Allerton Hospital, Rheumatology Unit [Siena], National Institute of Rheumatology and Physiotherapy, Instituto Poal de Reumatologia, Barcelona, Università degli studi di Torino (UNITO), Fundación Jiménez Díaz, Fundacion Jimenez Diaz [Madrid] (FJD), Center for Rheumatology and Spine Diseases, Copenhagen (Center for Rheumatology and Spine Diseases), VU University Medical Center [Amsterdam], Epidemiology and Data Science, Rheumatology, AII - Inflammatory diseases, Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Université Grenoble Alpes (UGA), Groupe de Recherche et d'Etudes du Processus Inflammatoire (GREPI), Université Joseph Fourier - Grenoble 1 (UJF), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), CHU Saint-Etienne-Hôpital de Bellevue, Délégation à la recherche clinique et aux innovations (DRCI), CHU de Clermont-Ferrand, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière, CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hôpital Claude Huriez-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Service de rhumatologie [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, CHU Cochin [AP-HP], Service de Rhumatologie [CHRU de Besançon], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Hôpital avicenne, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris 13 (UP13)-Hôpital Avicenne, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Médecine Interne [Rouen], Service d'Hépato-Gastroentérologie [Rouen], Unité de biostatistiques [Rouen], Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Ambroise Paré, fundacion Jimenez Diaz, VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest-Institut Brestois Santé Agro Matière (IBSAM), Università degli studi di Torino = University of Turin (UNITO), Service de Rhumatologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Rhumatologie [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut Brestois Santé Agro Matière (IBSAM), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Hôpital Charles Nicolle [Rouen], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Laboratoire de recherche européen pour la polyarthrite rhumatoïde (GenHotel - EA 3886), Université d'Évry-Val-d'Essonne (UEVE), and Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne
Subjects: Male, Genetics and Molecular Biology (all), Settore MED/16 - REUMATOLOGIA, [SDV]Life Sciences [q-bio], DMARDs (biologic), Severity of Illness Index, Biochemistry, Arthritis, Rheumatoid, 0302 clinical medicine, Disease Activity, Rheumatoid Arthritis, Ultrasonography, Rheumatology, Immunology, Biochemistry, Genetics and Molecular Biology (all), Immunology and Allergy, Rheumatoid, 030212 general & internal medicine, Prospective Studies, skin and connective tissue diseases, Prospective cohort study, ComputingMilieux_MISCELLANEOUS, Synovitis, biology, Doppler, Middle Aged, 3. Good health, Europe, Treatment Outcome, Rheumatoid arthritis, Antirheumatic Agents, Combination, [SDV.IMM]Life Sciences [q-bio]/Immunology, Drug Therapy, Combination, Female, medicine.symptom, medicine.drug, musculoskeletal diseases, Adult, medicine.medical_specialty, General Biochemistry, Genetics and Molecular Biology, Abatacept, 03 medical and health sciences, Drug Therapy, Predictive Value of Tests, Internal medicine, medicine, Humans, Aged, 030203 arthritis & rheumatology, business.industry, Arthritis, C-reactive protein, Ultrasonography, Doppler, Joint effusion, Clinical and Epidemiological Research, medicine.disease, Methotrexate, biology.protein, Physical therapy, Joints, business, Rheumatism, Biomarkers
Abstract: Objectives To study the responsiveness of a combined power Doppler and greyscale ultrasound (PDUS) score for assessing synovitis in biologic-naive patients with rheumatoid arthritis (RA) starting abatacept plus methotrexate (MTX). Methods In this open-label, multicentre, single-arm study, patients with RA (MTX inadequate responders) received intravenous abatacept (∼10 mg/kg) plus MTX for 24 weeks. A composite PDUS synovitis score, developed by the Outcome Measures in Rheumatology–European League Against Rheumatism (OMERACT–EULAR)-Ultrasound Task Force, was used to evaluate individual joints. The maximal score of each joint was added into a Global OMERACT–EULAR Synovitis Score (GLOESS) for bilateral metacarpophalangeal joints (MCPs) 2–5 (primary objective). The value of GLOESS containing other joint sets was explored, along with clinical efficacy. Results Eighty-nine patients completed the 24-week treatment period. The earliest PDUS sign of improvement in synovitis was at week 1 (mean change in GLOESS (MCPs 2–5): −0.7 (95% CIs −1.2 to −0.1)), with continuous improvement to week 24. Early improvement was observed in the component scores (power Doppler signal at week 1, synovial hyperplasia at week 2, joint effusion at week 4). Comparable changes were observed for 22 paired joints and minimal joint subsets. Mean Disease Activity Score 28 (C reactive protein) was significantly reduced from weeks 1 to 24, reaching clinical meaningful improvement (change ≥1.2) at week 8. Conclusions In this first international prospective study, the composite PDUS score is responsive to abatacept. GLOESS demonstrated the rapid onset of action of abatacept, regardless of the number of joints examined. Ultrasound is an objective tool to monitor patients with RA under treatment. Trial registration number NCT00767325.
Published: 2016
Full Text: View/download PDF

35. Bioelectrical impedance is an accurate method to assess body composition in obese but not severely obese adolescents

Author: Julien Verney, David Thivel, Charlotte Cardenoux, Bruno Pereira, Elodie Chaplais, Lore Metz, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Ferrand (UFR STAPS - UBP), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Unité de rééducation nutritionnelle et de réadaptation à l'activité physique, Centre Médical Infantile Romagnat, Department of Clinical Research and Innovation (DRCI), CHU Clermont-Ferrand, Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), and CHU Clermont-Ferrand-CHU Clermont-Ferrand
Subjects: Male, Pediatric Obesity, Adolescent, Intraclass correlation, Endocrinology, Diabetes and Metabolism, Concordance, [SDV]Life Sciences [q-bio], Analytical chemistry, 030209 endocrinology & metabolism, Body Mass Index, 03 medical and health sciences, Absorptiometry, Photon, 0302 clinical medicine, Endocrinology, bioimpedance, Electric Impedance, Humans, Medicine, 030212 general & internal medicine, Child, ComputingMilieux_MISCELLANEOUS, Adiposity, DXA, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, Reproducibility, Nutrition and Dietetics, Kilogram, business.industry, Body Weight, Reproducibility of Results, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, medicine.disease, Obesity, Bioimpedance Analysis, Body Composition, Female, business, Nuclear medicine, Bioelectrical impedance analysis, Body mass index, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
Abstract: The aim of this study was to compare total and segmental body composition results between bioimpedance analysis (BIA) and dual x-ray absorptiometry (DXA) scan and to test the reproducibility of BIA in obese adolescents. We hypothesized that BIA offers an accurate and reproducible method to assess body composition in adolescents with obesity. Whole-body and segmental body compositions were assessed by BIA (Tanita MC-780) and DXA (Hologic) among 138 (110 girls and 28 boys) obese adolescents (Tanner stage 3-5) aged 14 ± 1.5 years. The BIA analysis was replicated on 3 identical occasions in 32 participants to test the reproducibility of the methods. Whole-body fat mass percentage was significantly higher using the BIA method compared with DXA (40.6 ± 7.8 vs 38.8 ± 4.9%, P < .001), which represents a 4.8% overestimation of the BIA technique compared with DXA. Similarly, fat mass expressed in kilograms is overestimated by 2.8% using BIA (35.8 ± 11.7 kg) compared with the DXA measure (34.3 ± 8.7 kg) (P < .001), and fat-free mass is underestimated by − 6.1% using BIA (P < .001). Except for the right arm and leg percentage of fat mass, all the segmental measures of body composition are significantly different between the 2 methods. Intraclass correlation coefficient and Lin coefficient showed great agreement and concordance between both methods in assessing whole-body composition. Intraclass correlation coefficient between the 3 BIA measures ranged from 0.99 to 1 for body weight, body fat, and fat-free mass. Bioimpedance analysis offers an acceptable and reproducible alternative to assess body composition in obese adolescents, with however a loss of correlation between BIA and DXA with increasing body fat, its validity remains uncertain for segmental analysis among obese youth.
Published: 2016
Full Text: View/download PDF

36. Predictors of Trigeminal Neuropathy After Radiosurgery for Vestibular Schwannomas

Author: Philippe Cornu, Jean-Jacques Mazeron, C.A. Valery, Catherine Jenny, Ioannis Lamproglou, Mourad Aggad, Dominique Hasboun, Suhan Senova, Jean-Louis Golmard, Service de neuro-chirurgie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Unité de Radiochirurgie Gamma Knife, Region Ile De France, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de recherche clinique [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC), Service de Neuroradiologie [CHU Pitié-Salpêtrière], Algorithms, models and methods for images and signals of the human brain (ARAMIS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Inria de Paris, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Service d'Oncologie Radiothérapie [CHU Pitié Salpétrière], Service de neurochirurgie [CHU Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière] (CIC Paris-Est), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Inria de Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Unité de Recherche Clinique des hôpitaux Pitié-Salpêtrière – Charles Foix [CHU Pitié Salpêtrière] (URC PSL-CFX), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Direction de la Recherche Clinique et de l'Innovation [AP-HP] (DRCI), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Colliot, Olivier, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Inria de Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Direction de la Recherche Clinique et de l'Innovation [AP-HP] (DRCI), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Inria de Paris, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Adult, Male, Cancer Research, Multivariate analysis, Adolescent, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, medicine.medical_treatment, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [INFO.INFO-IM] Computer Science [cs]/Medical Imaging, Radiosurgery, 03 medical and health sciences, [INFO.INFO-CV] Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV], 0302 clinical medicine, medicine, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Humans, Dosimetry, Radiology, Nuclear Medicine and imaging, ComputingMilieux_MISCELLANEOUS, [SPI.SIGNAL] Engineering Sciences [physics]/Signal and Image processing, Aged, Retrospective Studies, Aged, 80 and over, Univariate analysis, Radiation, business.industry, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [INFO.INFO-CV]Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV], Radiotherapy Dosage, Retrospective cohort study, Neuroma, Acoustic, Middle Aged, Neuroma, medicine.disease, Radiation therapy, [SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, [INFO.INFO-TI] Computer Science [cs]/Image Processing [eess.IV], Oncology, Trigeminal Nerve Diseases, 030220 oncology & carcinogenesis, [INFO.INFO-TI]Computer Science [cs]/Image Processing [eess.IV], Female, Nuclear medicine, business, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, 030217 neurology & neurosurgery
Abstract: To analyze the relationship between dosimetric characteristics and symptoms related to trigeminal neuropathy (TN) observed after radiosurgery (RS) for vestibular schwannomas (VS); to propose guidelines to optimize planification in VS RS regarding TN preservation; and to detail the mechanism of TN impairment after VS RS.One hundred seventy-nine patients treated between 2011 and 2013 for VS RS and without trigeminal impairment before RS were included in a retrospective study. Univariate and multivariate analyses were performed to determine predictors of TN among characteristics of the patients, the dosimetry, and the VS.There were 20 Koos grade 1, 99 grade 2, 57 grade 3, and 3 grade 4. Fourteen patients (7.8%) presented a transitory or permanent TN. Between the patients with and without TN after VS RS, there was no significant difference regarding dosimetry or VS volume itself. Significant differences (univariate analysis P.05, Mann-Whitney test) were found for parameters related to the cisternal portion of the trigeminal nerve: total integrated dose, maximum dose, mean dose, volume of the Vth nerve (Volv), and volume of the Vth nerve receiving at least 11 Gy (VolVcist11Gy), but also for maximal dose to the Vth nerve nucleus and intra-axial portion (Dose maxVax). After multivariate analysis, the best model predicting TN included VolVcist11Gy (P=.0045), Dose maxVax (P=.0006), and Volv (P=.0058). The negative predictive value of this model was 97%.The parameters VolVcist11Gy, Dose maxVax, and Volv should be checked when designing dosimetry for VS RS.
Published: 2016

37. Patient education in chronic heart failure in primary care (ETIC) and its impact on patient quality of life: design of a cluster randomised trial

Author: Bruno Pereira, Catherine Laporte, Denis Pouchain, Jean-Yves Le Reste, Claude Dubray, Gilles Clément, Jean-Pierre Lebeau, Philippe Vorilhon, Jean-François Chenot, Gilles Tanguy, Marc Ruivard, Jean Cassagnes, Hélène Vaillant-Roussel, Departement Médecine Générale [Clermont-Ferrand], Université d'Auvergne - Clermont-Ferrand I (UdA), Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Service de Cardiologie Maladies Vasculaires [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], Service de Médecine Interne [CHU Clermont-Ferrand], Departement Médecine Générale [Brest] (Faculté de Médecine), Université de Brest (UBO), Departement Médecine Générale [Tours] (Faculté de Médecine), Université de Tours (UT), Department of General Practice [Greifswald, Germany] (Institute of Community Medicine), Universität Greifswald - University of Greifswald, Périnatalité, grossesse, Environnement, PRAtiques médicales et DEveloppement (PEPRADE), CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I (UdA), This trial received public funding (105 750 euros, 52%) from the French hospital research fund, a grant from the French Ministry of Health (PHRC-Hospital Program of Clinical Research) and regional health agencies (URCAM and GRSP), and private funding (97 500 euros, 48%) from Sanofi-Aventis, ‘le Groupe Pasteur mutualité’ (private medical insurance), and ‘Union régionale des médecins libéraux de la région Auvergne’ (regional primary care physician association)., Université de Tours, and VIGNAL, Alexine
Subjects: Male, Quality of life, Cluster-randomised controlled trial, medicine.medical_specialty, [SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Heart disease, law.invention, Study Protocol, Randomized controlled trial, Patient Education as Topic, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, law, Medicine, Humans, Cluster randomised controlled trial, Disease management (health), 10. No inequality, Aged, Heart Failure, Primary Health Care, business.industry, Disease Management, Patient education, Middle Aged, medicine.disease, Primary care, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, Clinical trial, Treatment Outcome, Heart failure, Chronic Disease, Physical therapy, Female, France, business, Family Practice
Abstract: Background Chronic heart failure, is increasing due to the aging population and improvements in heart disease detection and management. The prevalence is estimated at ~10% of the French general practice patient population over 59 years old. The primary objective of this study is to improve the quality of life for heart failure patients though a complex intervention involving patient and general practitioner (GP) education in primary care. Methods A randomised, cluster controlled trial, stratified over 4 areas of the Auvergne region in France comparing intervention and control groups. The inclusion criteria are: patients older than 50 years with New York Heart Association (NYHA) stage I, II, or III heart failure, with reduced ejection fraction or with preserved ejection fraction. Heart failure should be confirmed by the patient’s cardiologist according to the European Society of Cardiology guidelines criteria. The exclusion criteria include: severe cognitive disorders, living in an institution, participating in another clinical trial, having NYHA stage IV heart failure, or a lack of French language skills. The complex intervention consists of training at the GP practice with an interactive 2-day workshop to provide a patient’s education programme. GPs are trained to perform case management, lifestyle counselling and motivational interviewing, to educate patients on the main topics including clinical alarm signs, physical activity, diet and cardiovascular risk factors. The patients’ education sessions are scheduled at 1, 4, 7, 10, 13 and 19 months following the start of the trial. The primary outcome to be assessed is the impact on the quality of life as determined using two questionnaires: the Minnesota Living with Heart Failure Questionnaire and SF-36. To detect a difference in the mean quality of life at 19 months, we anticipate studying a minimum of 400 patients from 80 GPs. Discussion This trial will provide insight into the effectiveness of a complex intervention to educate patients with heart failure including a 2-day GP workshop and patients’ education programme in the setting of a GP consultation to improve the quality of life in patients with chronic heart failure. This complex intervention tool could be used during initial and further medical training. Trial registration ETIC is a cluster-randomised, controlled trial registered on ClinicalTrials.gov [NCT01065142, 2010, Feb 8] and the French drug agency [Agence Nationale de Sécurité du Médicament et des produits de santé; registration number: 2009-A01142-55, on March 5th, 2010]. Electronic supplementary material The online version of this article (doi:10.1186/s12875-014-0208-3) contains supplementary material, which is available to authorized users.
Published: 2014
Full Text: View/download PDF

38. Perception of therapeutic patient education in heart failure by healthcare providers

Author: Patrick Jourdain, Yves Juillière, Christian Hervé, François Alla, Laure Garbacz, Gaëlle Guyon, Henry Coudane, Frédérique Claudot, Pratiques professionnelles : aspects méthodologiques, éthiques et juridiques (ETHOS), Université de Lorraine (UL), Laboratoire Ethique Politique et Santé (EA 4569), Université Paris Descartes - Paris 5 (UPD5), Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Centre Hospitalier René Dubos [Pontoise], Délégation à la Recherche Clinique et à l'Innovation [CHRU Nancy] (DRCI), Pratiques professionnelles : aspects méthodologiques, éthiques et juridiques ( ETHOS ), Université de Lorraine ( UL ), Laboratoire Ethique Politique et Santé ( EA 4569 ), Université Paris Descartes - Paris 5 ( UPD5 ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), CIC-Nancy, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Délégation à la Recherche Clinique et à l'Innovation - DRCI [CHU Nancy], and Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy]-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Health Knowledge, Attitudes, Practice, MESH : Health Knowledge, Attitudes, Practice, MESH: Health Knowledge, Attitudes, Practice, MESH : Professional-Family Relations, 030204 cardiovascular system & hematology, MESH: Health Care Surveys, Relation de soin, MESH: Perception, Therapeutic patient education, MESH: Patient Participation, 0302 clinical medicine, Professional-Family Relations, Surveys and Questionnaires, Medicine, 030212 general & internal medicine, media_common, Communication, MESH: Life Style, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, MESH : Physician-Patient Relations, 3. Good health, MESH: Risk Reduction Behavior, MESH: Communication, Care relationship, France, MESH : Communication, Cardiology and Cardiovascular Medicine, MESH : Surveys and Questionnaires, MESH : Life Style, medicine.medical_specialty, Attitude of Health Personnel, media_common.quotation_subject, MESH: Attitude of Health Personnel, Éducation thérapeutique du patient, MESH: Patient Education as Topic, 03 medical and health sciences, Nursing, Patient Education as Topic, Perception, Humans, MESH : Health Care Surveys, MESH : Perception, MESH: Surveys and Questionnaires, MESH : France, Professional practices, MESH: Professional-Family Relations, Life Style, Heart Failure, Physician-Patient Relations, MESH: Humans, business.industry, Pratiques professionnelles, MESH : Humans, medicine.disease, MESH : Risk Reduction Behavior, MESH : Patient Participation, Insuffisance cardiaque, MESH: France, Family medicine, Heart failure, Health Care Surveys, MESH: Heart Failure, MESH: Physician-Patient Relations, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Patient Education as Topic, Patient Participation, business, MESH : Heart Failure, Healthcare providers, Risk Reduction Behavior, MESH : Attitude of Health Personnel
Abstract: International audience; BACKGROUND:Care provider support for therapeutic patient education (TPE), its results and relationships with patients are factors in the setting up and sustainability of this practice.AIM:With a view to understanding the factors determining TPE care provider participation and favouring its development, the aim of this study was to describe the perception healthcare providers have of TPE in heart failure.METHODS:A national survey by self-administered questionnaire was performed in 2013 in 61 Observatoire de l'INsuffisance cardiaque (ODIN; Heart Failure Observatory) centres participating in the I-CARE programme. The cardiologist in charge of each centre received five questionnaires: one for him/herself and four for other healthcare providers working with him/her.RESULTS:We received 116 responses out of the 305 questionnaires sent (38.0%). Almost all of the responders stated that the patients were more observant after TPE sessions (91.4%). According to the responders, patients were better informed thanks to TPE (53.9%); they stated that TPE had changed their relationships with patients (81.9%); they also felt that they were educating the patient's close family/friends at the same time as the patients (86.2%).CONCLUSION:The survey showed that TPE improves care relationships. Healthcare providers recognize that they have been working differently since the programme was set up, and want the patient's close family/friends to be involved in treatment.
Published: 2014
Full Text: View/download PDF

39. CANABIC: CANnabis and Adolescents: effect of a Brief Intervention on their Consumption - study protocol for a randomized controlled trial

Author: Bruno Falissard, Paul Frappé, Gilles Clément, D. J. Costa, Gilles Tanguy, Philippe Vorilhon, Catherine Laporte, Mélanie Badin, Yoann Gaboreau, Claude Dubray, Laurent Marty, Bruno Pereira, Pierre-Michel Llorca, Olivier Blanc, Hélène Vaillant-Roussel, CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I (UdA), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Service de psychiatrie adulte - B, Département de médecine générale, Université Jean Monnet - Saint-Étienne (UJM), Université de Montpellier (UM), Université Joseph Fourier - Grenoble 1 (UJF), Health anthropologist, Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Troubles du comportement alimentaire de l'adolescent (UMR_S 669), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Périnatalité, grossesse, Environnement, PRAtiques médicales et DEveloppement (PEPRADE), This study was supported by a grant from the French Ministry of Health (PHRC-Hospital Program of Clinical Research, n°0505, 2011)., Etablissement National d'Enseignement Supérieur Agronomique de Dijon (ENESAD), Département de Médecine Générale, Faculté de Médecine, Université Clermont Auvergne, Unité de Biostatistiques [CHU Clermont-Ferrand], Département de Médecine Générale [Clermont-Ferrand], Faculté de Médecine - Clermont-Auvergne (FM - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Jean Monnet [Saint-Étienne] (UJM), Techniques pour l'Evaluation et la Modélisation des Actions de la Santé (TIMC-IMAG-ThEMAS), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), International Space University (ISU), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), BMC, Ed., Biostat Unit, Centre Hospitalier Universitaire de Clermont-Ferrand, Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), CHU Gabriel Montpied (CHU), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), CIC - Clermont Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), CHU Gabriel Montpied ( CHU ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux ( NPsy-Sydo ), CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I ( UdA ), Délégation à la Recherche Clinique et à l'Innovation ( DRCI ), Université Jean Monnet [Saint-Étienne] ( UJM ), Université de Montpellier ( UM ), Université Joseph Fourier - Grenoble 1 ( UJF ), Institut National de la Santé et de la Recherche Médicale ( INSERM ), Troubles du comportement alimentaire de l'adolescent ( UMR_S 669 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ), Périnatalité, grossesse, Environnement, PRAtiques médicales et DEveloppement ( PEPRADE ), and Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Research design, Health Knowledge, Attitudes, Practice, Marijuana Abuse, Time Factors, General Practice, 030508 substance abuse, Medicine (miscellaneous), law.invention, Study Protocol, 0302 clinical medicine, Randomized controlled trial, Clinical Protocols, law, Medicine, Pharmacology (medical), 030212 general & internal medicine, Young adult, ComputingMilieux_MISCELLANEOUS, biology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General medicine, Brief intervention, 3. Good health, Treatment Outcome, Research Design, France, 0305 other medical science, Adult, medicine.medical_specialty, Automobile Driving, Adolescent, Alcohol Drinking, MEDLINE, Marijuana Smoking, 03 medical and health sciences, Young Adult, Humans, Psychiatry, Cannabis, Consumption (economics), business.industry, biology.organism_classification, Adolescents and young adults, Clinical research, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Adolescent Behavior, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Psychotherapy, Brief, Perception, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business
Abstract: International audience; BACKGROUND: Cannabis is the most consumed illegal substance in France. General practitioners (GPs) are the health professionals who are most consulted by adolescents. Brief intervention (BI) is a promising care initiative for the consumption of cannabis, and could be a tool for GPs in caring for adolescents who consume cannabis. The aim of the CANABIC study is to measure the impact of a BI carried out by a GP on the consumption of cannabis by adolescents of 15 to 25 years of age. METHODS: A randomized clustered controlled trial, stratified over three areas (Auvergne, Languedoc-Roussillon, and Rhone-Alps), comparing an intervention group, which carries out the BI in consultation, and a control group, which ensures routine medical care. The main assessment criterion is the consumption of cannabis by amount of joints per month, at 12 months. The amount necessary to highlight a significant difference between the two groups of 30 % of consumption at 12 months is 250 patients (50 GPs, 5 patients per GP; risk alpha = 5 %; power = 90 %; intra-cluster correlation coefficient rho = 0.2; Hawthorne effect = 15 %; lost to follow-up rates for GPs = 10 % and for patients = 20 %). This plan is replicated for the three areas, and therefore a total of 750 patients are expected.The secondary criteria for judgment are the associated consumption of tobacco and alcohol, the perception of the consequences of consumption, and the driving of a vehicle following consumption. DISCUSSION: Research about BI for young cannabis users is underway. The aim of the CANABIC study is to validate a BI suited to adolescents who consume cannabis, which may be performed in the general practice. This would provide a tool for their treatment by a GP, which could be widely distributed during initial or further medical training.Trial registration: CANABIC is a randomized clustered trial (NCT01433692, registered 2011 Sept 12), PHRC funded: Clinical Research Hospital Program (Governmental Fund, Health Ministry). Date first patient randomized: March 2012.
Published: 2014
Full Text: View/download PDF

40. Evaluation of atorvastatin efficacy and toxicity on spermatozoa, accessory glands and gonadal hormones of healthy men: a pilot prospective clinical trial

Author: Florence Brugnon, Joël R. Drevet, Anne-Sophie Gremeau, Bruno Pereira, Laurent Janny, Igor Tauveron, Benoit Sion, Geneviève Grizard, Hanae Pons-Rejraji, Salwan Maqdasy, Geoffroy Marceau, Gerald Gouby, Génétique, Reproduction et Développement (GReD), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire BDR CECOS - FIV AMP, CHU Estaing [Clermont-Ferrand], Neuro-Dol (Neuro-Dol), Université d'Auvergne - Clermont-Ferrand I (UdA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Délégation à la Recherche Clinique et à l'Innovation (DRCI), CHU Clermont-Ferrand, service de Biostatistiques, DRCI, Centre Hospitalier Universitaire de Clermont-Ferrand, Laoratoire de Biochimie, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Unité de Biostatistiques [CHU Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Service d'Endocrinologie-Diabétologie, CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], Laboratoires d'Hématologie et de Biochimie, Hôtel-Dieu-CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I (UdA), This study was supported by a local hospital grant from the Hospital Clinical Research Program of the French Ministry of Health (PHRC L 06 Tauveron), and the DRCI of Clermont-Ferrand university hospital. The authors thank Elizabeth Petit and Dr. Christine Rondanino for revising the English language., and Autard, Delphine
Subjects: Male, [SDV]Life Sciences [q-bio], Atorvastatin, Pilot Projects, [SDV.GEN] Life Sciences [q-bio]/Genetics, chemistry.chemical_compound, Endocrinology, Testis, Testosterone, [SDV.BDD]Life Sciences [q-bio]/Development Biology, ComputingMilieux_MISCELLANEOUS, [SDV.BDD.GAM]Life Sciences [q-bio]/Development Biology/Gametogenesis, Epididymis, [SDV.BA]Life Sciences [q-bio]/Animal biology, Prostate, Obstetrics and Gynecology, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Spermatozoa, 3. Good health, Cholesterol, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, Asthenozoospermia, Healthy men, lipids (amino acids, peptides, and proteins), Gonadal Hormones, medicine.drug, Adult, medicine.medical_specialty, Statin, medicine.drug_class, Down-Regulation, Context (language use), Semen, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Antispermatogenic Agents, Normocholesterolemic, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, Biology, [SDV.BDLR.RS]Life Sciences [q-bio]/Reproductive Biology/Sexual reproduction, Young Adult, Semen quality, Internal medicine, medicine, Humans, Pyrroles, Seminal fluid, Spermatogenesis, [SDV.GEN]Life Sciences [q-bio]/Genetics, Acrosome Reaction, Research, [SDV.BDLR]Life Sciences [q-bio]/Reproductive Biology, medicine.disease, Reproductive Medicine, chemistry, Heptanoic Acids, Normozoospermic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Biomarkers, Gonadotropins, Human Spermatozoa, Developmental Biology, Hormone
Abstract: International audience; BACKGROUND: Recommendations for cardiovascular disease prevention advocate lowering both cholesterol and low-density lipoprotein cholesterol systemic levels, notably by statin intake. However, statins are the subject of questions concerning their impact on male fertility. This study aimed to evaluate, by a prospective pilot assay, the efficacy and the toxicity of a decrease of cholesterol blood levels, induced by atorvastatin on semen quality and sexual hormone levels of healthy, normocholesterolaemic and normozoospermic men. METHODS: Atorvastatin (10 mg daily) was administrated orally during 5 months to 17 men with normal plasma lipid and standard semen parameters. Spermatozoa parameters, accessory gland markers, semen lipid levels and blood levels of gonadal hormones were assayed before statin intake, during the treatment, and 3 months after its withdrawal. RESULTS: Atorvastatin treatment significantly decreased circulating low-density lipoprotein cholesterol (LDL-C) and total cholesterol concentrations by 42% and 24% (p
Published: 2014
Full Text: View/download PDF

41. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Author: Najiby Kassis-Chikhani, Samira Fafi-Kremer, Olivier Schwartz, Laurent Bélec, Matthieu Prot, Cyril Planchais, Timothée Bruel, Laura Courtellemont, Florence Guivel-Benhassine, Artem Baidaliuk, Isabelle Staropoli, Julien Le Guen, Etienne Simon-Loriere, Laurent Hocqueloux, Delphine Planas, David Veyer, Pierre Gantner, Maaran Michael Rajah, Aurélie Velay, Thierry Prazuck, Dhiaeddine Edriss, Félix A. Rey, Françoise Porrot, Hélène Péré, Floriane Gallais, Aymeric Sève, Nicolas Robillard, Julien Puech, Hugo Mouquet, Virus et Immunité - Virus and immunity (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Vaccine Research Institute [Créteil, France] (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors [CRC] (FunGeST), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Génomique évolutive des virus à ARN - Evolutionary genomics of RNA viruses, Institut Pasteur [Paris] (IP), Université Paris Cité (UPCité), Immunologie humorale - Humoral Immunology, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Strasbourg, Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional d'Orléans (CHRO), Virologie Structurale - Structural Virology, The Opera system was co-funded by the Institut Pasteur and the Région Île de France (DIM1Health). Work in the O.S. laboratory is funded by the Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Médicale (FRM), ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2 and IDISCOVR. Work in UPBI is funded by grant ANR-10-INSB-04-01 and the Région Île-de-France program DIM1-Health. D.P. is supported by the Vaccine Research Institute. The H.M. laboratory is funded by the Institut Pasteur, the Milieu Intérieur Program (ANR-10-LABX-69-01), INSERM, REACTing, EU (RECOVER) and Fondation de France (00106077) grants. The S.F.K. laboratory is funded by Strasbourg University Hospitals (SeroCoV-HUS, PRI 7782), the Programme Hospitalier de Recherche Clinique (PHRC N 2017–HUS no. 6997), the Agence Nationale de la Recherche (ANR-18-CE17-0028), Laboratoire d’Excellence TRANSPLANTEX (ANR-11-LABX-0070_TRANSPLANTEX) and the Institut National de la Santé et de la Recherche Médicale (UMR_S 1109). The E.S.-L. laboratory is funded by the Institut Pasteur and the French Government’s Investissement d’Avenir programme, Laboratoire d’Excellence ‘Integrative Biology of Emerging Infectious Diseases’ (grant no. ANR-10-LABX-62-IBEID)., We thank N. Casartelli for critical reading of the manuscript, P. Guardado Calvo for discussion, the individuals who participated in the study, members of the Virus and Immunity Unit for discussions and help, N. Aulner and the UTechS Photonic BioImaging (UPBI) core facility (Institut Pasteur), a member of the France BioImaging network, for image acquisition and analysis, and the DRCI, CIC, Médecine du Travail and Pôle de Biologie teams (CHU de Strasbourg) for the management of the Strasbourg cohort and serology testing., ANR-10-LABX-0077,VRI,Initiative for the creation of a Vaccine Research Institute(2010), ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), ANR-20-COVI-0059,PROTEO-SARS-CoV-2,Protéomique du SARS-CoV-2(2020), ANR-10-INBS-0004,France-BioImaging,Développment d'une infrastructure française distribuée coordonnée(2010), ANR-10-LABX-0069,MILIEU INTERIEUR,GENETIC & ENVIRONMENTAL CONTROL OF IMMUNE PHENOTYPE VARIANCE: ESTABLISHING A PATH TOWARDS PERSONALIZED MEDICINE(2010), ANR-18-CE17-0028,HuMABK,Les anticorps monoclonaux humains : une Nouvelle approche thérapeutique contre l'infection par le virus BK et les maladies associées(2018), ANR-11-LABX-0070,TRANSPLANTEX,Nouveaux loci d'histocompatibilité/biomarqueurs en transplantation humaine: de la découverte à l'app(2011), European Project: 101003589, H2020-SC1-PHE-CORONAVIRUS-2020,RECOVER(2020), Virus et Immunité - Virus and immunity, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Vaccine Research Institute (VRI), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École pratique des hautes études (EPHE), Institut Pasteur [Paris], Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPC)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPC), and Université Paris Cité (UPC)
Subjects: Male, Delta, COVID-19 Vaccines, medicine.drug_class, India, Alpha (ethology), Biology, Antibodies, Monoclonal, Humanized, Antibodies, Viral, Monoclonal antibody, Neutralization, Epitope, Epitopes, Immune system, Neutralization Tests, medicine, Humans, Immune Evasion, Multidisciplinary, COVID-19, Convalescence, Middle Aged, Antibodies, Neutralizing, Virology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Spike Glycoprotein, Coronavirus, Monoclonal, biology.protein, France, Antibody
Abstract: The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India1–5. Since then, it has become dominant in some regions of India and in the UK, and has spread to many other countries6. The lineage includes three main subtypes (B1.617.1, B.1.617.2 and B.1.617.3), which contain diverse mutations in the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein that may increase the immune evasion potential of these variants. B.1.617.2—also termed the Delta variant—is believed to spread faster than other variants. Here we isolated an infectious strain of the Delta variant from an individual with COVID-19 who had returned to France from India. We examined the sensitivity of this strain to monoclonal antibodies and to antibodies present in sera from individuals who had recovered from COVID-19 (hereafter referred to as convalescent individuals) or who had received a COVID-19 vaccine, and then compared this strain with other strains of SARS-CoV-2. The Delta variant was resistant to neutralization by some anti-NTD and anti-RBD monoclonal antibodies, including bamlanivimab, and these antibodies showed impaired binding to the spike protein. Sera collected from convalescent individuals up to 12 months after the onset of symptoms were fourfold less potent against the Delta variant relative to the Alpha variant (B.1.1.7). Sera from individuals who had received one dose of the Pfizer or the AstraZeneca vaccine had a barely discernible inhibitory effect on the Delta variant. Administration of two doses of the vaccine generated a neutralizing response in 95% of individuals, with titres three- to fivefold lower against the Delta variant than against the Alpha variant. Thus, the spread of the Delta variant is associated with an escape from antibodies that target non-RBD and RBD epitopes of the spike protein. The SARS-CoV-2 Delta variant partially evades neutralization by several monoclonal antibodies and by sera from individuals who have had COVID-19, but two doses of anti-COVID-19 vaccines still generate a strong neutralizing response.
Published: 2021
Full Text: View/download PDF

42. The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes

Author: Xavier Belenfant, Philippe Rouvier, Pierre Ronco, Isabelle Brocheriou, Emmanuel Esteve, Michèle Saïdi, David Buob, Tim Ulinski, Sophie Tuffet, Hanna Debiec, Zahir Amoura, Makoto Miyara, Des Maladies Rénales Rares aux Maladies Fréquentes, Remodelage et Réparation, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service d'Anatomie et cytologie pathologiques [CHU Pitié-Salpêtrière] (ACP), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Néphrologie et Dialyses [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche Clinique de l’Est Parisien [CHU Saint-Antoine] (URC-EST), Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (CHNO)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Rothschild [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de médecine interne et d'immunologie clinique [CHU Pitié-Salpêtrière], Centre Hospitalier Intercommunal André Grégoire [Montreuil] (CHI André Gregoire), Service de néphrologie et pédiatrie générale [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Trousseau [APHP], Service d'Anatomie et cytologie pathologiques = Service de Pathologie [CHU Pitié-Salpêtrière] (ACP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Département de Néphrologie = Service de Néphrologie et Dialyses [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Direction de la Recherche Clinique et de l'Innovation [AP-HP] (DRCI), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Département de médecine interne et immunologie clinique [CHU Pitié-Salpêtrière] (DMIIC), CHU Trousseau [APHP], HAL-SU, Gestionnaire, and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP]
Subjects: Pathology, medicine.medical_specialty, 030232 urology & nephrology, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 03 medical and health sciences, 0302 clinical medicine, renal biopsy, systemic lupus erythematosus, Membranous nephropathy, Research Letter, medicine, skin and connective tissue diseases, 030304 developmental biology, 0303 health sciences, Systemic lupus erythematosus, medicine.diagnostic_test, business.industry, membranous nephropathy, medicine.disease, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 3. Good health, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, Nephrology, [SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunology, exostosin, immunohistochemistry, Immunohistochemistry, Renal biopsy, business
Abstract: International audience; Exostosin (EXT) 1 and EXT2 proteins are recently discovered major components of the subepithelial deposits in a subset of patients with membranous nephropathy (MN).1,2 Although the detection of EXT1/2 seems to be a distinctive feature of MN related to systemic lupus erythematosus (SLE),1 the exact frequency of EXT-positive, SLE-associated MN (SLE-MN) and its potential clinical significance are not well determined.Here, we retrospectively evaluated 86 consecutive patients with biopsy-proven pure class 5 SLE-MN diagnosed between January 2010 and December 2018 in 2 nephropathology centers (La Pitié Salpêtrière and Tenon hospitals) in Paris, France; mixed classes (3 + 5 and 4 + 5 of the 2003 ISN/Renal Pathology Society classification)3 were excluded.
Published: 2021
Full Text: View/download PDF

43. Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact

Author: Stefan D. Anker, Ruddy Richard, Guillaume Clerfond, Yves Boirie, Pierre-Louis Tartière, Clément Riocreux, Patrick Rossignol, Bruno Pereira, Géraud Souteyrand, Nicolas Combaret, Marie Blanquet, Marie-Claire D'Agrosa Boiteux, Pascal Motreff, Aurélien Mulliez, Pelle Stolt, Frédéric Jean, Romain Eschalier, Grégoire Massoullié, CHU Clermont-Ferrand, SIGMA Clermont (SIGMA Clermont), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, CH Mauriac, Biostatistics Unit (Department of Clinical Research and Innovation), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Clinique Médicale Cardio-Pneumologie de Durtol, Maglia Rotta, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), ROSSI, Sabine, Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), and Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, 0301 basic medicine, Sarcopenia, Longitudinal study, medicine.medical_specialty, Acute decompensated heart failure, Decompensated chronic heart failure, 030209 endocrinology & metabolism, Decompensation, Critical Care and Intensive Care Medicine, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Activities of Daily Living, Prevalence, Humans, Medicine, In patient, Longitudinal Studies, Prospective Studies, Aged, Aged, 80 and over, Heart Failure, 030109 nutrition & dietetics, Nutrition and Dietetics, Hand Strength, business.industry, musculoskeletal system, medicine.disease, Chronic heart failure, 3. Good health, Hospitalization, body regions, Clinical trial, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, Cross-Sectional Studies, Dysmobility, Cohort, Female, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, human activities
Abstract: International audience; Background & aims: Sarcopenia is a multifactorial syndrome resulting in a decrease in both muscle mass and function. Little is known about the prevalence and prognostic impact of sarcopenia in patients with acutely decompensated chronic heart failure (ADHF). We aimed to evaluate the prevalence (main endpoint) and impact of sarcopenia on ADHF patients.Methods: 140 ADHF patients were enrolled between November 2014 and September 2018 in a multi-center prospective longitudinal study. A similar, independent multi-departmental cross-sectional study in 165 ADHF patients was used for external validation of prevalence data. All subjects were assessed on the European Working Group on Sarcopenia criteria.Results: Ninety-one patients (65%) had sarcopenia (vs. 53.6% in the external replication regional cohort). Patients with sarcopenia were older and more likely to have eGFR
Published: 2021
Full Text: View/download PDF

44. Quantity Metrics and Proxy Indicators to Estimate the Volume and Appropriateness of Antibiotics Prescribed in French Nursing Homes: A Cross-sectional Observational Study Based on 2018 Reimbursement Data

Author: Maïa Simon, Céline Pulcini, Marlies E J L Hulscher, Ouarda Pereira, Jeroen Schouten, Nathalie Thilly, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Direction régionale du service du contrôle médical du Grand Est (DRSM), Radboud University Medical Center [Nijmegen], Unité de Méthodologie, Data Managment et Statistiques, Département Méthodologie, Promotion, Investigation (DMPI), Délégation à la Recherche Clinique et à l'Innovation (DRCI), [CHRU Nancy], Service des Maladies Infectieuses et Tropicales [CHRU Nancy], and Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
Subjects: 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, 030106 microbiology, Psychological intervention, Context (language use), 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Environmental health, medicine, Humans, Antimicrobial stewardship, 030212 general & internal medicine, Proxy (statistics), Reimbursement, Descriptive statistics, business.industry, Public health, Anti-Bacterial Agents, Nursing Homes, 3. Good health, Benchmarking, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Cross-Sectional Studies, Infectious Diseases, Observational study, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, business
Abstract: Background Antibiotic resistance is an increasing threat to public health globally. Indicators on antibiotic prescribing are required to guide antibiotic stewardship interventions in nursing homes. However, such indicators are not available in the literature. Our main objective was to provide a set of quantity metrics and proxy indicators to estimate the volume and appropriateness of antibiotic use in nursing homes. Methods Recently published articles were first used to select quantity metrics and proxy indicators, which were adapted to the French nursing home context. A cross-sectional observational study was then conducted based on reimbursement databases. We included all community-based nursing homes of the Lorraine region in northeastern France. We present descriptive statistics for quantity metrics and proxy indicators. For proxy indicators, we also assessed performance scores, clinimetric properties (measurability, applicability, and room for improvement), and conducted case-mix and cluster analyses. Results A total of 209 nursing homes were included. We selected 15 quantity metrics and 11 proxy indicators of antibiotic use. The volume of antibiotic use varied greatly between nursing homes. Proxy indicator performance scores were low, and variability between nursing homes was high for all indicators, highlighting important room for improvement. Six of the 11 proxy indicators had good clinimetric properties. Three distinct clusters were identified according to the number of proxy indicators for which the acceptable target was reached. Conclusions This set of 15 quantity metrics and 11 proxy indicators may be adapted to other contexts and could be used to guide antibiotic stewardship programs in nursing homes.
Published: 2021
Full Text: View/download PDF

45. Metformin and everolimus in neuroendocrine tumours: A synergic effect?

Author: Julien Forestier, Philip Robinson, Catherine Lombard-Bohas, Gérald Raverot, Laurent Milot, Annie Lemelin, Françoise Borson-Chazot, Lucia Hue-Fontaine, Thomas Walter, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Délégation à la recherche clinique et à l'innovation [CHU Dijon] (DRCI), and Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)
Subjects: Male, Oncology, medicine.medical_specialty, Lung Neoplasms, endocrine system diseases, [SDV]Life Sciences [q-bio], Population, Antineoplastic Agents, Neuroendocrine tumors, Digestive System Neoplasms, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Diabetes mellitus, Diabetes Mellitus, medicine, Clinical endpoint, Humans, Hypoglycemic Agents, Everolimus, Prospective cohort study, education, Aged, education.field_of_study, Univariate analysis, Hepatology, business.industry, Gastroenterology, Drug Synergism, Middle Aged, medicine.disease, Metformin, Progression-Free Survival, 3. Good health, Neuroendocrine Tumors, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract: To explore potential synergy in effectiveness between metformin and everolimus, 2 inhibitors of the mTOR pathway, for neuroendocrine tumours (NET).A cohort of patients with advanced gastroenteropancreatic or lung NETs treated by everolimus were stratified in to those without diabetes, those with diabetes and without metformin, and those with diabetes with metformin. The primary endpoint was the median progression-free survival (PFS).A total of 213 patients were included, 165 of which were non-diabetic; among diabetic patients, 19 were treated with metformin and 29 with others anti-diabetic drugs. No significant difference in median PFS [95%CI] was found between the three groups: 10.05 months [8.27;11.83] for non-diabetic patients, 15.24 [19.88;49.43] for diabetic w/metformin, and 9.03 months [4.01;14.06] for diabetic w/o metformin group. In univariate analysis, factors significantly associated with longer PFS was a functioning NET, a number of metastatic sites3, the absence of lung metastasis, and an uptake on Octreoscan®, but not the absence of metformin use; only uptake on Octreoscan® remained significant in multivariate analysis.In contrast with the literature, we did not find a synergy between everolimus and metformin in NET. Prospective studies are underway to improve the comprehension of the potential synergy regarding population and tumour type.
Published: 2020
Full Text: View/download PDF

46. Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition

Author: Maud Privat, Mathis Lepage, Yves-Jean Bignon, Ioana Molnar, Sandrine Viala, Flora Ponelle-Chachuat, Mathias Cavaillé, Mathilde Gay-Bellile, Nancy Uhrhammer, Yannick Bidet, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, and COLO, Mouniati
Subjects: Male, Cancer Research, Candidate gene, Colorectal cancer, [SDV]Life Sciences [q-bio], Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, MLH3, Biology, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Genetics, medicine, Humans, Genetic Predisposition to Disease, FANCM, education, Research Articles, education.field_of_study, panel sequencing, Cancer, medicine.disease, Colorectal Neoplasms, Hereditary Nonpolyposis, 3. Good health, [SDV] Life Sciences [q-bio], predisposition to cancer, MRE11A, breast and ovarian cancer syndrome, Genetic Loci, 030220 oncology & carcinogenesis, Mutation, hereditary colorectal cancer, Hereditary Breast and Ovarian Cancer Syndrome, Female, Ovarian cancer, candidate genes, Research Article
Abstract: Hereditary predisposition to cancer concerns between 5 and 10% of cancers. The main genes involved in the most frequent syndromes (hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome) were identified in the 1990s. Exploration of their functional pathways then identified novel genes for hereditary predisposition to cancer, and candidate genes whose involvement remains unclear. To determine the contribution of truncating variants in 11 candidate genes (BARD1, FAM175A, FANCM, MLH3, MRE11A, PMS1, RAD50, RAD51, RAD51B, RINT1 and XRCC2) to cancer predisposition in a population of interest, panel sequencing was performed in 849 patients with a suspected hereditary predisposition to cancer for whom a diagnostic panel of 38 genes identified no causal mutation. Sixteen truncating variants were found in FANCM (n = 7), RINT1 (n = 4), RAD50 (n = 2), BARD1, PMS1 and RAD51B. FANCM (adjusted p-value: 0.03) and RINT1 (adjusted p-value: 0.04) were significantly associated with hereditary breast and ovarian cancer. However, further studies are required to determinate the risk of cancer, including the segregation of the variants in the families of our cases. No mutation was identified in RAD51, MRE11A, FAM175A, XRCC2, or MLH3. The involvement of these genes in the hereditary predisposition to cancer cannot be ruled out, although if it exists it is rare or does not seem to involve truncating variants. This article is protected by copyright. All rights reserved.
Published: 2020
Full Text: View/download PDF

47. Continuous Wound Infiltration With Ropivacaine After Mastectomy: A Randomized Controlled Trial

Author: Angeline Ginzac, Guillaume Gayraud, Pierre Gimbergues, Emilie Monrigal, Marie Beguinot, Dominique Joly, Fabrice Kwiatkowski, Guillaume Le Bouedec, Médipole Hôpital Mutualiste Villeurbanne, Institut du Sein, Clinique Clémentville, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, and GINZAC, Angeline
Subjects: Visual analogue scale, medicine.medical_treatment, [SDV.CAN]Life Sciences [q-bio]/Cancer, law.invention, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, [SDV.CAN] Life Sciences [q-bio]/Cancer, Randomized controlled trial, law, medicine, Humans, Ropivacaine, Anesthetics, Local, Mastectomy, ComputingMilieux_MISCELLANEOUS, Aged, Pain, Postoperative, business.industry, Chronic pain, Middle Aged, medicine.disease, 3. Good health, Catheter, Continuous wound infiltration, 030220 oncology & carcinogenesis, Anesthesia, Morphine, Female, 030211 gastroenterology & hepatology, Surgery, business, Anesthesia, Local, medicine.drug
Abstract: Background To evaluate the efficacy of continuous wound infiltration with ropivacaine to reduce acute postoperative pain in patients undergoing mastectomy for carcinoma of the breast. Materials and methods A randomized, double-blind, placebo-controlled trial was conducted. One hundred fifty patients were randomly assigned to receive continuous ropivacaine (0.2%) (group A, n = 74) or saline solution (0.9%) (group B, n = 76) at 10 mL/h for 48 h through a multilumen catheter placed during the surgical procedure. Postoperative morphine consumption and visual analog scale (VAS) pain scores were recorded. A quality of life score (Quality of life questionnaire Core 30) and a VAS score were obtained at 1, 3, and 6 mo after surgery. Results The difference in mean morphine consumption between the two groups was close to significance during the first 48 h postsurgery (P = 0.056; 10.8 ± 16.5 versus 4.8 ± 10.4 mg). At day 1, patients in the ropivacaine-infusion group had lower morphine consumption than the control group (P = 0.0026). The link between local ropivacaine infiltration and a decrease in mean postoperative VAS scores reached significance for the first 24 h postsurgery (P = 0.039). No significant difference was found between the two arms for VAS pain scores (P = 0.36) or for quality of life (overall QLQ-C30 score, P = 0.09) at 1, 3, or 6 mo. Conclusions Continuous wound infiltration with ropivacaine is efficacious in reducing postoperative pain. Quality of life and chronic pain at 1, 3, and 6 mo were not improved by ropivacaine wound infiltration.
Published: 2020
Full Text: View/download PDF

48. Assessment of oro-dental manifestations in a series of acromegalic patients, the AcroDent study

Author: Marie Batisse-Lignier, Joannice Thevenon, Lemlih Ouchchane, Nathalie Pham Dang, Philippe Caron, Christian Dualé, Salwan Maqdasy, Igor Tauveron, Laurent Devoize, Sylvain Roumeau, DEVOIZE, Laurent, CHU Clermont-Ferrand, Université Clermont Auvergne (UCA), Image Science for Interventional Techniques (ISIT), Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université-Centre National de la Recherche Scientifique (CNRS), Génétique, Reproduction et Développement (GReD), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA), Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service Diabétologie [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
Subjects: Panoramic radiograph, Endocrinology, Diabetes and Metabolism, Population, Dentistry, 030209 endocrinology & metabolism, lcsh:Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, Gingivitis, 0302 clinical medicine, Endocrinology, Quality of life, Acromegaly, Internal Medicine, Medicine, education, Exostosis, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, education.field_of_study, lcsh:RC648-665, business.industry, Research, 030206 dentistry, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, medicine.disease, Chronic periodontitis, Hypercementosis, oral manifestations, quality of life, acromegaly, medicine.symptom, business, periodontal diseases, growth hormone-secreting pituitary adenoma
Abstract: Objective: The dental and periodontal impact of GH/IGF-1 hypersecretion has been poorly investigated until now. Our aim is to precisely describe the oro-dental state of acromegalic patients and to study the impact of GH/IGF-1 hypersecretion on patients’ reported oral health-related quality of life (OHRQoL). Methods: After collecting characteristics of their disease, acromegalic patients answered the GOHAI questionnaire assessing their OHRQoL, the AcroQoL questionnaire and then benefited from a complete stomatological and radiological examination (orthopantomogram systematically, retro-alveolar radiography or Cone Beam CT if necessary). Results: In total, 29 patients aged 59.1 ± 16.0 years were included. The average DMFT index (sum of Decayed, Missing and Filled Teeth per patient) was 19.0 ± 7.8. 16/29 patients had a gingivitis and 18/29 a mild to moderate chronic periodontitis, but no case of severe chronic periodontitis was found, probably because the frequency of a protective thick gingival biotype was increased (9/29). No case of generalized gingival hypertrophy or diffuse hypercementosis was observed. According to the Add-GOHAI score, only 8/26 patients had a satisfactory OHRQoL. This parameter was correlated to the acromegaly-specific quality of life according to the AcroQoL score. Interestingly, 11/29 patients had bulky oral bony outgrowths (OBO), such as large maxillary or mandibular tori and multiple vestibular exostosis. Conclusions: The unsatisfactory OHRQoL reported by acromegalic patients contrasts with a rather good objective oro-dental state and annual oral examination seems relevant in this population. Finally, we report that huge OBO could be helpful signposts for the diagnosis of acromegaly.
Published: 2020
Full Text: View/download PDF

49. Effect of high intensity interval training on body composition in women before and after menopause: a meta‐analysis

Author: Marcelo Luis Marquezi, Nathalie Boisseau, Florie Maillard, Marine Dupuit, Bruno Pereira, Antonio Herbert Lancha, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Escola de Educação Física e Esporte, Universidade de São Paulo (USP), Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), and Universidade de São Paulo = University of São Paulo (USP)
Subjects: Adult, medicine.medical_specialty, Physiology, ERGOMETRIA, High-Intensity Interval Training, Intra-Abdominal Fat, 030204 cardiovascular system & hematology, Overweight, Body weight, women, Interval training, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Physiology (medical), Weight Loss, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Medicine, Obesity, Aged, Nutrition and Dietetics, Postmenopausal women, business.industry, abdominal fat mass, Postmenopausal state, fat mass, General Medicine, Middle Aged, medicine.disease, Menopause, Meta-analysis, Body Composition, Physical therapy, Female, medicine.symptom, business, High-intensity interval training, 030217 neurology & neurosurgery
Abstract: International audience; New findings: What is the topic of this review? A meta-analysis of the efficacy of high intensity interval training (HIIT) in reducing weight, total fat mass (FM) and (intra)-abdominal FM in normal-weight and overweight/obese women before and after menopause. What advances does it highlight? HIIT programmes in women significantly decrease body weight and total and abdominal FM. Their effects are more evident in pre- than in postmenopausal women. Cycling HIIT seems more effective than running, especially in postmenopausal women, and training interventions longer than 8 weeks comprising three sessions a week should be promoted.Abstract: High-intensity interval training (HIIT) is a stimulating modality for reducing body weight and adipose tissue. The purpose of this meta-analysis was to assess the efficacy of HIIT in reducing weight, total fat mass (FM) and (intra)-abdominal FM in normal-weight and overweight/obese women before and after menopause. A structured electronic search was performed to find all publications relevant to our review. Stratified analyses were made of hormonal status (pre- vs. postmenopausal state), weight, HIIT modalities (cycling vs. running), programme duration (< or ≥8 weeks) and the methods used to measure body composition (dual-energy X-ray absorptiometry vs. computed tomography, Magnetic Resonance Imaging and others). A total of 38 studies involving 959 subjects were included. Our meta-analysis showed that overall HIIT programmes significantly decrease weight, total and abdominal FM in women. Both normal weight and overweight/obese women lost total FM after HIIT protocols whereas HIIT was only effective in decreasing abdominal FM in women with excess adiposity. When pre- and postmenopausal women were considered separately, the effect of HIIT on weight, total and abdominal FM were only significant before menopause. Cycling HIIT seemed more effective than running, especially in postmenopausal women, and training interventions longer than 8 weeks comprising three sessions were more efficient. HIIT is a successful strategy to lose weight and FM in normal weight and overweight/obese women. However, further studies are still needed to draw meaningful conclusions about the real effectiveness of HIIT protocols in postmenopausal women.
Published: 2020
Full Text: View/download PDF

50. Two new reliable immunohistochemical methods for simultaneous identification of capillaries, the three types of fibers and basal lamina in human skeletal muscle

Author: Julien Verney, Bruno Pereira, Mélina Bailly, Amandine Boileau, Bogdan Galusca, David Thivel, Natacha Germain, Daniel Courteix, Christophe Hourdé, Léonard Féasson, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Auvergne (UFR STAPS - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM ), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Troubles du Comportement Alimentaire, Addictions et Poids Extêmes (TAPE - TCA), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), TAPE laboratory [Saint-Étienne], and Université Jean Monnet [Saint-Étienne] (UJM)
Subjects: 0301 basic medicine, Histology, Capillary action, Muscle Fibers, Skeletal, Antigens, CD34, Basement Membrane, 03 medical and health sciences, [SDV.MHEP.AHA]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], medicine, Humans, Capillary supply, Fiber, Muscle fibre, Molecular Biology, Combined staining method, Reproducibility, 030102 biochemistry & molecular biology, Chemistry, Antibodies, Monoclonal, Skeletal muscle, Cell Biology, Immunohistochemistry, Muscle fiber type, Capillaries, Medical Laboratory Technology, 030104 developmental biology, medicine.anatomical_structure, CD31, Basal lamina, Metabolic profile, Biomedical engineering
Abstract: International audience; Capillary network of skeletal muscle has a crucial role in oxygen supply and is strongly associated with the phenotype and metabolic profile of muscle fibers. Abundant literature has explored capillarization of skeletal muscle in different populations and in response to different interventions. Capillary and fiber type identification techniques have considerably evolved over the last decades, but to the best of our knowledge, no validated immunohistochemical method has yet been developed to simultaneously identify capillaries (using CD31), the three different muscle fiber types, and basal lamina. Nine human muscle biopsies of vastus lateralis were stained using 5 different methods to test: the reliability of different CD31 antibodies for capillary identification, the reliability between single-section or serial-section methods, and the intra-experimenter reproducibility in visual detection of capillaries. High reliability for the different antibodies directed against capillaries was observed for capillary contacts (CC) measurements (intra-class correlations (ICC) [ICC95%] of 0.89 [0.72; 0.96] for type I fibers, 0.93 [0.81; 0.97] for type IIA fibers, 0.88 [0.71; 0.96] for type IIX fibers, 0.95 [0.86; 0.98] for all fiber types) as well as a high level of similarity between single and serial sections methods. A strong similarity in capillary analysis between the different methods was obtained for each sample measurements. Analysis of Lin's concordance correlation coefficients and Bland and Altman's graphics showed a strong intra-experimenter reproducibility. This article proposes two time- and tissue-sparing immunohistochemical methods to accurately assess a complete fiber typing (type I, IIA, and IIX) along with muscle capillarization on a single muscle section.
Published: 2020
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

427 results on '"DRCI"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources